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ABSTRACT
Studying the Efficacy of an Injectable 3-Dimensional Fibrin Extracellular Matrix to Characterize
the Effects of Antitumor Agents on SW620 Cells in A Microfluidic Device
Thèo Anastos
Colorectal cancer is the third most common cancer in the United States and there is currently a
lot of research going into new antitumor agents to kill the cancer. One method for replicating the tumor
response to a drug in vivo is by creating an in vitro drug testing model to replicate the in vivo condition.
This research project was conducted to determine the efficacy of testing tumor cultures in a microfluidic
device as a way to provide accurate drug responses in vitro instead of using in vivo subjects in clinical
trials. A total of four experiments were conducted with each experiment increasing the complexity of the
culture model. The first experiment was a 2-dimensional tumor culture that was seeded in a well plate to
study how 5-fluorouracil treatments affected the tumor cell viability. The second experiment was a 2dimensional tumor culture that was seeded on top of a fibrin extracellular matrix (ECM) gel to determine
how the tumor cells would respond to the 5-luorouracil treatments while growing on the fibrin. The third
experiment was to create a 3-dimensional tumor culture that was seeded inside the fibrin ECM gel. This
experiment was conducted to determine if tumor cells cultured within the fibrin gel could receive
nutrients from the medium diffusing through the gel. Once the tumors responded as expected in the
fibrin gel, the gel could be injected into a microfluidic device for the fourth experiment. The fourth
experiment was a proof of concept to determine if the tumor cells could survive in the microfluidic device
and be properly treated with 5-fluorouracil. The experiment with the cells seeded in the well plates
showed that an increase in 5-fluorouracil concentration caused a significant decrease in cell viability. Both
fibrin gel experiments showed that the average tumor size, total tumor area, and tumor count decreased
as the 5-fluorouracil concentration increased. The tumor cells were successfully able to be cultured in the
microfluidic device and the average tumor size decreased significantly when the culture was exposed to
the 5-fluorouracil treatment.
Keywords: colorectal cancer, microfluidic device, 5-fluorouracil, confocal imaging
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Chapter 1
INTRODUCTION
Colorectal Cancer
According the American Cancer Society, colorectal cancer is the third most common cancer in the
United States with 104,610 new cases of colon cancer and 43,340 new cases of rectal cancer in 2020.
While being the third most common, it is also the third leading cause of cancer-related deaths in men and
women. Colorectal cancer is expected to cause 53,200 deaths during 2020. The lifetime risk of developing
colorectal cancer is about 4.3% for men and 4.1% for women [1]. Fortunately, the death rate has been
dropping for the past several decades due to improving screening methods which lead to finding and
removing colorectal polyps before they can develop into cancers. According to the CDC, colorectal cancer
accounts for 11% of all cancer treatment costs in the United States and colorectal cancer has an estimated
$14.1 billion annual medical cost for American patients.
Current screening methods for colorectal cancer include sigmoidoscopy, colonoscopy, fecal
immunochemical testing (FIT), guaiac-based fecal occult blood (gFOB) testing, and multi-target stool DNA
(mt-sDNA) testing. A sigmoidoscopy screens for tumors in the rectum and the lower part of the large
intestine, which is less invasive than a standard colonoscopy because a colonoscopy screens the entire
colon. An FIT test screens for hidden blood in the stool, which is often an early precursor for colon cancer.
The FIT test will only detect blood from the lower intestines. A gFOB test is similar to the FIT test in that it
tests for pseudo-peroxidase activity of hemoglobin in the feces. Lastly, a mt-sDNA test screens for
biomarkers for neoplasia, or any uncontrolled growth, in the colon. The newest screening method is mtsDNA testing, which does reduce colorectal cancer incidences and mortalities, however, it is a less
effective screening strategy for the cost compared to the other screening options [21]. Once the screen
comes back positive, the patient needs to undergo treatment.
The ideal treatment for colorectal cancer is to completely remove the tumor and metastases by
surgical intervention. Unfortunately, even with all the current screening methods, a quarter of colorectal
cancer tumors are diagnosed at an advanced stage where there are already signs of metastases, resulting
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in difficulties with surgically controlling the tumors and leading to patient deaths [22]. Either in
combination with surgery, or as a standalone treatment option, chemotherapy and targeted therapy are
other treatment methods that are currently being used. One of the mainstream approaches for
chemotherapy is a combination of 5-fluorouracil, irinotecan, oxaliplatin, and capecitabine [22]. Patients at
low risk of deterioration are commonly given single-agent therapy with only one of the mentioned drugs.
Targeted therapies can directly inhibit the cell proliferation, differentiation, and migration of cancer cells
in a patient by using chemicals that specifically target the cancer microorganisms [22]. With the
emergence of new chemotherapy and targeted therapy agents, the need for a testing platform to mimic
in vivo conditions arises.
Tumor Cell Biology
The fundamental feature of a cancerous cell is tumor clonality, which is the development of
tumors from single cells after they proliferate abnormally [23]. Tumor formation occurs from the
differentiation patterns of a pool of cells. Tumors are highly metabolic and they need vascular networks.
This means that the body has to use energy to create new vascular networks and the tumors will consume
more energy to continue proliferating. The first step in the process of cancer development is tumor
initiation. Tumor initiation is caused by a genetic alteration which leads to abnormal proliferation of a
single cell [23]. This proliferation in the cell eventually leads to a population of clonally derived tumor
cells. The next step is tumor progression, which is generally classified when additional mutations are seen
within the cells of the tumor population [23]. Clonal selection can then occur when the mutations start to
give the cells a selective advantage. The most common mutation is the ability for more rapid growth. With
the advantages the mutations provide the tumor population, a new clonally derived colony of tumor cells
which have evolved on the advantages of the mutation will become the dominant population [23]. The
clonal selection process continues throughout the tumor development process, so the cells that make up
the tumor continuously become more malignant and grow at an increasing pace.
For colon carcinomas, the earliest stage in tumor development is increased proliferation of
epithelial cells in the colon [23]. Once the increased proliferation starts, a small abnormal growth of cells
2

is formed and through clonal selection the cells begin to act malignant. Once the tumor cell population is
malignant, the cancer cells can penetrate the wall of the colon and spread to other abdominal organs
such as the bladder or small intestine [23]. Because colonic stem cells undergo apoptosis, or cell death, if
they get damaged, they are located deep in colonic crypts where they are covered with mucin from other
cells. The colonic crypts are a single sheet of columnar epithelial cells that are organized into crypts and
are constantly self-renewing [2]. The colonic stem cells in these crypts produce potential mutagenic
molecules via the Mdr1 (multidrug resistance 1) plasma membrane protein. [3]. In a healthy individual,
the colonic stem cells divide into two daughter cells with only one of the cells proceeding to undergo
differentiation. The other daughter cell gets sloughed from the surface and therefore loses its opportunity
to become cancerous.
From a molecular perspective, colorectal tumors involve multisequential steps along the
adenoma-to-carcinoma transition with the inactivation of tumor suppressor genes and oncogene
activation [2]. With colorectal cancer, genomic instability can occur with chromosomal instability,
microsatellite instability, and CpG Island Methylator Phenotype pathways [3]. The chromosomal instability
pathway includes genetic changes which activate protooncogenes and inactivates tumor suppression
genes. Protooncogenes code for proliferation proteins, so an activation of these genes can lead to
increased protein expression and therefore cell hyperactivity. Microsatellite instability is caused by
germline mutations in one of the mismatch repair genes. An error in the mismatch repair system will
result in the genome having different length microsatellites than the parent cell which will affect the
expression of that gene. Specific to colorectal cancer, the mismatch repair disfunction causes epigenetic
silencing of MLH1 gene expression by promoter hypermethylation [3]. Patients with colorectal cancer
have epigenetic regulation via inappropriate methylation of gene promoter regions. CpG (cytosine
phosphodiester bonded to guanosine) methylation occurs when a methyl group covalently attaches to
cytosine. In healthy cells, CpG islands are kept in an unmethylated state so the gene is expressed
normally. During hypermethylation of these islands, the promoter gene is silenced so the gene cannot be
expressed normally [3]. After the gene is silenced, the growth and differentiation of the cells are altered
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and the methylation results in a predisposition state that precedes tumor formation in the colon [24]. An
example of aberrant methylation is with the CXLC12 chemokine ligand. When this ligand gets methylated
in human colorectal cancer, it can foster the metastatic property of that colon cancer cell line [24].
Colorectal cancer is considered a heterogeneous group of malignancies instead of a single
disease arising within the colon. Mutations in the KRAS, NRAS, and BRAF oncogenes occur in 55-60% of
colorectal cancers, and unfortunately, patients with these gene mutations don’t benefit from anti-EGFR
(epidermal growth factor receptor) therapies [1]. EGFR inhibitors administered in anti-EGFR therapies
cause the cells to stop growing and dividing. Resistance to these therapies is detrimental to the patient
because the tumor cells will continue to be malignant and spread throughout the body. These mutations
counteract the activity of anti-EGFR drugs by the constitutive activation of EGFR downstream signaling
cascades [25]. In other words, even though the drug is being administered, the effects of the drug are
being overridden by the mutation signaling the pathway instead. Due to this resistance, an anti-tumor
drug with a different method of action needed to be selected for these experiments.
SW620 Cells
The SW620 cell line is the lymph node metastasis of the SW480 primary/pre-metastatic
colorectal tumor. This means that the SW620 cell line is malignant and therefore the cells have a faster
growth rate than the SW480 cell line. Additionally, the SW620 cell line, although developed from the
same genetic background as the SW480 cell line, have more cancer stem cells compared to the SW480
cell line [4]. The increased cancer stem cells should mean that the SW620 cell line is more chemoresistant
because of the cancer stem cells ability to self-renew and differentiate into heterogenous lineages of
cancer cells [26]. The SW620 cell line synthesizes small quantities of carcinoembryonic antigens (CEAs)
which are a set of glycoproteins involved in cell adhesion and aids in the dissemination of colorectal
cancer cells throughout the colon.
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Current Research with SW620 Culture Models
Animal models are currently being used to gain a deeper knowledge of diseases, such as cancer,
and provide analysis on drug effects in vivo. However, animal models can be expensive, time consuming,
and will often fail to predict human responses during clinical trials [5]. Researchers have estimated that
only 8% of successful animal trials for cancer drugs were able to translate to a successful human clinical
trial [6]. The reason for the low success rate in these trials is because of the physiological and pathological
differences in cell and tumor biology across species.
Other models currently used include 2D cell monocultures and 3D cell monocultures. Although
2D cultures can be used as a cost-effective option for drug screening. The main advantage of a 2D cell
culture, aside from its cost, is the simplicity of use. However, these 2D cultures fail to replicate the 3D
spatial arrangement cells conform to in vivo. As a result, 2D cultures have poor predictive power when
evaluating a drug response in the human body. 3D cultures significantly improve on the results from using
a 2D culture because 3D environments can promote more changes in cellular morphology, function, and
responses to stimuli [7]. Unfortunately, 3D cultures still oversimplify the cellular mechanisms and tissue
architecture in their in vivo counterparts [7].
5-Fluorouracil as a Treatment Option
As mentioned earlier, the most common treatment options for colorectal cancer are
chemotherapy and surgery. According to the American Cancer Society, radiation is also sometimes used
either pre-surgery to help shrink the tumor to make it easier to remove, or post-surgery to kill any cancer
cells left behind. For chemotherapy, a combination of anti-tumor agents, commonly including 5fluorouracil, are administered to the patient. In some situations, 5-fluorouracil was the only drug
administered in the chemotherapeutic trial [22]. Because of the clinical success of 5-fluorouracil (5-FU), it
lends itself well to be used as a prototypical therapy for assessing our model system.
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Figure 1: 5-Fluorouracil Molecular Structure. The molecular comparison between the DNA
component uracil and the pharmaceutical compound 5-fluorouracil
This compound was first developed in 1957 by Dushinsky as an anti-cancer solution for liver
cancers. The liver cancer would absorb the 5-FU and it would interrupt DNA and RNA replication by acting
as an analogue to uracil. On a molecular level, 5-FU is uracil with the 5th carbon fluorinated. The simple,
yet impactful difference can be seen in Figure 1. 5-Fluorouracil acts as a thymidylate synthase (TS)
inhibitor, and interrupting the action of this enzyme blocks the synthesis of pyrimidine thymidine, a
nucleoside required for DNA or RNA replication. 5-FU is a heterocyclic aromatic organic compound with a
structure similar to that of the pyrimidine molecules-- such as thymines, cytosines, and uracils-- of DNA
and RNA. Due to its structure, 5-FU interferes with nucleoside metabolism and can be incorporated into
RNA and DNA, leading to cytotoxicity and cell death of solid tumor cells [8]. This interference prevents
tumors from continual growth and leads to the tumors shrinking in size. Since being developed, 5-FU has
been utilized to treat a range of cancers, including colorectal cancer [8].
5-FU is an analog of uracil which acts as a pyrimidine antagonist meaning it blocks the synthesis
of pyrimidine nucleotides, such as uracil. This makes 5-FU a good candidate as an anti-cancer treatment
because it can decrease the cancerous DNA synthesis and repair. One of the mechanisms of action
exhibited by 5-FU is the fluorouracil metabolite fluorodeoxyuridine monophosphate (FdUMP) which
competes with the primary unaltered uracil. FdUMP binds with thymidylate synthetase (TS) and the folate
cofactor, resulting in decreased thymidine production and therefore decreased DNA synthesis, repair, and
cell proliferation [8]. Another mechanism of action that has been identified involves the 5-FU metabolite
fluorodeoxyuridine triphosphate (FdUTP) becoming incorporated into DNA and damaging the DNA,
therefore decreasing cell proliferation [8]. The last mechanism of action identified involves the
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chemotherapy’s metabolite fluorouridine-5-triphosphate (FUTP) becoming incorporated into RNA in place
of uridine triphosphate (UTP). This results in RNA damage thus interfering with RNA processing and
protein synthesis. Ultimately, this leads to fewer viable cells and the shrinkage of tumors [9].
Viability studies have been conducted using 96 well plates as the culture platform. A study done
by the Biomedical Biotechnology Research Unit, Department of Biochemistry and Microbiology, Rhodes
University, tested cell viability with anti-cancer drug treatments by plating SW620 and SW480 cell lines in
96 well plates and treating them 5-fluorouracil and other anti-cancer drugs. A proliferation agent was
added to measure absorbance with a spectrophotometer and the concentration to cause a cell viability
shift by 50% was calculated [4].
The cells in the work covered by this report were treated with 5-FU as a way to validate the drug
response model in the 2D and 3D tumor cultures. Because 5-FU had been shown to be effective in
reducing tumor size in the SW620 cell line, seeing tumor size reduction in the experiments meant the
model could be validated [4]. A different study also confirmed 5-FU as an effective way to inhibit
colorectal cancer cell growth by using a CCK-8 assay to analyze the effect of different concentrations of 5FU on SW620 cells during a 48-hour treatment [11]. By establishing the model with 5-FU and getting
results on par with the previous experiments a tumor culture model can be developed to test unknown
drugs and mimic a response to the drug.
Culture Conditions
In order to mimic an in vivo environment, SW620 cells are cultured in an incubator set to 37⁰C
and 5% C02. The human body has an average temperature of 37⁰ and the C02 percentage is important to
assure the culture media stays at an appropriate pH level mimicking in vivo pH. The base RPMI (Roswell
Park Memorial Institute) media used had phenol red added which changes from red to either yellow or
pink if the pH drops below 6.6 or spikes above 8 pH, respectively.
The first experiment for this thesis research required the SW620 cells to be cultured in a 96 well
plate over the course of 96 hours. The wells have a working volume of 200µL but the cells were cultured
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in 100µL of complete RPMI because 100µL of a viability assay reagent also needed to be added. After the
cells were initially deposited into the wells, they were given a 48-hour period to properly adhere to the
wells before being treated by the drug. Another 48-hour period was given to let the drug interact with the
cells. To prep the samples for spectrophotometry, the CellTiter-Glo luminescent cell viability assay kit was
used. The CellTiter-Glo reagent is used to determine the number of viable cells in culture based on the
quantitation of the ATP present. The more metabolically active cells in the sample means the more ATP
the reagent will react with. ATPases work by hydrolyzing one of the phosphate bonds in ATP to form ADP.
The energy released from the breakdown of the bonds can then be analyzed to quantify the amount of
ATP initially in the sample. Using a spectrophotometer, an absorbance value for each well will be given
which corresponds to the amount of ATP in each well. A spectrophotometer works by directing a beam of
light at a diffraction grating within the machine, the grating works like a prism and separates the light. The
different component wavelengths of the light then interact with the sample and the detector measures
the absorbance of the sample.
Once a cell density range which responded to the drug treatment was established in the 96 well
plates, the next step in validating the final response model was to create a 2D monoculture on a fibrin
extracellular matrix (ECM). The advantages of using a 2D monoculture is that they are simple and lowmaintenance but can still produce accurate results [10]. The 2D experiments used in this thesis research
project aimed to test the cell densities and drug concentrations that would be desirable in the viability
experiment. If the expected drug response occurred, then the same treatment groups could be used for a
3D experiment. The cells in this experiment were cultured in a chamber slide instead of a 96 well plate.
The working volume of the wells in the chamber slides were 500µL which provided appropriate space for
an 80uL fibrin gel and 250µL of complete RPMI media. Unfortunately, when using a 2D culture to analyze
a drug response, there are several disadvantages with the accuracy compared to an in vivo environment.
For example, cells in a 2D culture do not mimic the natural structures of tumors, because cell-cell and cellECM environment interactions are not represented as they would be in a tumor mass [10]. Among these
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interactions are differentiation, proliferation, and gene expression, which are all important when studying
the cells’ response to a stimulus such as the drug treatment.
By being able to successfully culture cells as a 3D model, the problems experienced with a 2D
culture to in vivo comparison can be mitigated. In terms of in vivo imitation, the 3D culture model allows
the cells and tumors grown to be in 3D, causing the cells to respond to antitumor agents differently,
better mimicking in vivo conditions. Additionally, the creation of proper interactions of cell-cell and cellECM environment better mimic the in vivo conditions the model is based from. The cell-cell interactions
differ in 2D because the changed morphology from a 2D tumor causes the cells to have a different
structural organization and different cell signaling mechanisms [10]. Additionally, the cell-environment
interactions are different for 2D tumors because the top layer of cells has an infinite supply of media from
the cells having direct contact with the media. Additionally, the cells in a 3D culture have a diverse
phenotype and polarity. The cells in a 3D culture will also have the same expression of genes, splicing,
topology, and biochemistry as they would in vivo [10]. After the cell densities and drug concentrations
have been tuned to achieve the desired tumor response, the 3D gel can be plated in a microfluidic device
instead of the chamber slide. Unfortunately, the 3D gel model also has its disadvantages. It is difficult to
obtain tumor spheres and there is low repeatability of results [10]. The low repeatability of the results
occurs because of the high variability in the gel geometry and the variability of cell dispersion throughout
the gel for each trial. Another downside for 3D models is the difficulty of immunofluorescence staining of
the tumor spheres [10]. However, in this experiment, the SW620 cells were transfected to express GFP so
no staining was necessary once the cells were plated in the gel.
Evaluating Drug Efficacy in a 2D Assay
The first step in getting a working model using microfluidic devices to mimic in vivo drug
responses is to establish a range of cell densities and drug concentrations to allow for proper evaluation.
The ideal cell density range is the lowest cell density that can still survive the highest drug dosage
treatment and that the highest cell density is one that does not overcrowd the culture and mitigate the
effects of the lowest drug dosage. Similarly, the ideal drug concentration range is such that the lowest
9

drug concentration can still show a significant effect compared to the control group, and the highest drug
concentration cannot exterminate all the cells in the lowest cell density groups. This range of drug
concentrations revolves around the EC50 (half maximal effective concentration) of the 5-FU. The EC50
value of a drug is the concentration needed to achieve a half-maximal response. So, the more potent the
drug is, the smaller the EC50 will be. A dose response curve can be created to obtain the EC50 value.
The cultures are evaluated using a luminescent viability assay because the assay is more sensitive
to changes in cell metabolism than the changes that can be observed with microscopy. Additionally, the
ATP assay is the fastest and least prone to artifacts, such as cellular debris and compound fluorescence,
when compared to other viability assay methods [12]. When cells lose membrane integrity, they can no
longer synthesize ATP therefore the endogenous ATPases deplete all remaining ATP in the cytoplasm [12].
The way these ATPase viability assays, like the CellTiter-Glo assay used in the experiment, provide a
luminescent output is by lysing the cells and then stabilizing the ATP that is released. Luciferin is used as a
substrate in these assays and the stable form of luciferase can catalyze the reaction that generates
photons of light from the released ATP [12].
Other assay options include a resazurin reduction assay and a protease viability marker assay
concept. The resazurin reduction is a redox indicator that can permeate cell membranes and be used to
monitor viable cell number. A viable cell with an active metabolism will reduce resazurin into the
resorufin product, which is a fluorescent pink [12]. Unlike the ATPase assay, the resazurin assay requires
the reagent to be exposed to the cells for several hours, instead of 10 minutes. The protease viability
marker assay is a measurement of constitutive and conserved protease activity within viable cells. The
assay involves a fluorogenic protease substrate that can selectively detect protease activity which is
restricted to viable cells [12]. For this assay, a fluorometer is used instead of a spectrophotometer. Due to
the time and instrument limitations for the other assay options, the ATPase assay was the best choice for
this experiment. The objective of the viability assay experiment was to find the optimal range of cell
densities to initially plate to provide tumor growth within a 96-hour period as well as respond to the drug
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treatment. Once the experimental model was able to achieve the expected response, the cell densities
were then used as a baseline for culturing the first 2D ECM experiment.
Fibrin as a Culture Substrate
After the cell densities and drug concentrations have been determined, the next step is to move
the testing from a well plate with no substrate into a chamber slide with a fibrin ECM hydrogel as a
culture substrate. When cells are cultured on a flat surface, they display abnormal polarization, loss of
differentiated phenotypes, and an altered response to pharmaceutical reagents [13]. These limitations are
the reason why hydrogels can help better mimic the native in vivo environment. Fibrin is a natural
polymer which results from the selective cleavage of the dimeric glycoprotein fibrinogen by the serine
protease thrombin. The fibrin molecules interact through disulfide bonds and additional fibrin crosslinking
can occur when thrombin activates Factor XIIIa [13]. Increasing the thrombin content when making the
fibrin gels can result in the gels having thinner fibrils and smaller pores [13]. Additionally, because the
cells are only cultured for 96 hours on the gels, the problem of protease-mediated degradation won’t be
experienced. Another positive of using fibrin is that the conversion of fibrinogen to fibrin was found to
enhance SW620 cell recruitment [28]. One study was successful in creating a 3D in vitro culture by
embedding tumor cells into a fibrin matrix. It was found that fibrin acted as a physiological ECM that
supported tumor angiogenesis in vivo [29]. The literature supports the fact that SW620 tumors can be
successfully cultured and studied in a fibrin culture substrate.
Microfluidic Devices
Microfluidic models allow for studying the pathologic and physiologic interactions occurring in
tissue and organ microenvironments. These devices, coined “organ-on-a-chip”, can mimic the in vivo
biological conditions where therapies would take effect. One of the main advantages of using this 3D
microenvironment is that it can reproduce cell confinement, a parameter that cells undergo as they move
in the interstitial space of tissues in the human body, which cannot be replicated in 2D cultures. Cell
confinement is necessary for studying the behavior of motile cells, such as cancer cells, and being able to
define the physiopathological responses of these cells to treatments [14,15]. One study was able to
11

successfully create a novel microfluidic platform to recreate interconnected 3D immune and tumor
systems. Their microfluidic device allowed the researchers to study the behavior of dendritic cells toward
SW620 cells after treatment with antitumor agents [14]. This study validates the ability to culture SW620
cancer cells in a microfluidic environment and being able to treat the cells with antitumor agents.
Using a hydrogel as an artificial extracellular matrix inside a microfluidic device gets researchers
closer to replacing in vivo models with 3D in vitro models because the cellular microenvironment inside
the device can more closely resemble human physiological conditions. Cells seeded in hydrogels inside a
microfluidic device have spatial orientation and cellular interactions that more closely mimic in vivo
conditions [32]. One of the advantages of inserting a hydrogel in the device is that the hydrogels can allow
fluid pathways throughout the device which accelerates the distribution of nutrients from the media to
the cells [32].
In a 2D model, the lack of proper cell-cell and cell-ECM interaction causes abnormal proliferation,
polarization, abnormal gene expression, and abnormal cell signaling [32]. These issues are less apparent
when the cells are no longer cultured in a monolayer for adherent cells. A 3D tumor model provides
proper cellular morphology for the tumor culture but still lacks some of the structural complexities found
in vivo. With a 3D tumor model, the accuracy of the model when compared to in vivo can be increased by
injecting the 3D gel into a microfluidic device. The main advantage of culturing cells in a microfluidic
device instead of in a chamber slide is being able to provide the cells with continuous flow of media
instead of a stagnant media supply. The microfluidic device gives all the other advantages of having a 3D
cell culture while getting one step closer to truly mimicking the human in vivo environment by providing
media perfusion. Additionally, the device can be vascularized to provide more support for the cell
cultures. In this research project, the 3D gel was cultured in a microfluidic device for 96 hours to
determine the drug response on tumor size while best mimicking the in vivo environment.
The microfluidic devices used in these experiments were constructed using
poly(dimethylsiloxane) (PDMS), an organic, silicon-based polymer. PDMS is often the material of choice in
microfluidic cell applications because it is readily available and prototyping with PDMS is not complicated.
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Additionally, PDMS is suitable for cell culture applications because of its biocompatibility and sterilizability
[16]. After construction, the optically clear PDMS devices were plasma bonded to glass microscope slides
to seal the device and allow the chamber to be imaged with a confocal microscope. Plasma bonding uses
surface activation, the process of altering the surface energy of a material, to increase the adhesion
potential of that material. This process allows the PDMS to better adhere to the glass slides. The study
mentioned earlier, which used a microfluidic device to study dendritic cells and SW620 cells, fabricated
their devices by creating a PDMS replica and plasma bonding it onto a microscope glass slide. These
devices were able to support passive diffusion of media, oxygen, and other molecular components [14].
This study validates the efficacy of using PDMS devices to culture SW620s and study the effect of
antitumor agents on the cells.
Evaluating Drug Efficacy in a Gel Culture
Culturing cells in a hydrogel requires in situ imaging to properly evaluate the drug efficacy in the
culture. The hydrogels are fabricated on glass chamber slides enabling high-resolution imaging.
Additionally, the SW620 cells are transfected to produce green fluorescent protein (GFP) allowing the cells
to be imaged with fluorescent microscopy. Drug efficacy can be quantified by the decrease in tumor size
and number when introduced to the drug. To measure the tumor size, confocal microscopy can be used
to image the spheroid composition of the tumors. Researchers were able to successfully analyze
colorectal cancer spheroids by fixing the cells in paraformaldehyde and staining the cells with Green
Fluorescent Nucleic Acid Stain to then be imaged with a confocal microscope [30]. The study used a zstack analysis to image spheroids for multiple colorectal cell lines, including SW620s, in order to
determine their shape. The study also took orthogonal cross-sections of x-y focal planes and
reconstructed them as x-z or y-z planes. Additionally, the ImageJ software was used to identify the
spheroids and count cell nuclei [30]. This experiment validated the method of using z-stack imaging with a
confocal microscope to characterize tumor size, and therefore drug efficacy. By comparing the difference
in tumor size between experimental groups, a conclusion can be made about the 5-FU treatment causing
the cancer cells to reduce proliferation or undergo apoptosis.
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To study the effect of the drug treatment on the tumors in the microfluidic devices, a confocal
microscope can be used to image the tumors across the geometry of the device. Brightfield imaging can
also be used with the confocal microscope to align the microfluidic device chambers with the objective.
The confocal microscope can take images across the entire device geometry and then stitch the images
together to display all the tumors throughout the device. 3D reconstruction confocal images of the
devices can be acquired by taking z-stack slices and editing them to show the 3D representation with the
same image type and size of each 2D image [14]. This imaging technique makes it easy to compare tumor
size across the drug treatment groups and the control because the brightness and distribution of the
fluorescence can be used to determine the number of cells and tumor boundaries in a region.
Confocal Microscopy
Imaging samples on a confocal microscope provides the user with the capability to capture
images of a 3D sample at different depths within the sample. Additionally, confocal microscopes can
eliminate or reduce any background information away from the focal plane to prevent image degradation
and the user can collect serial optical sections from their sample [32]. With confocal microscopy, cells can
be specifically labeled with fluorescent molecules using immunostaining methods, in this case the SW620
cells were transduced to express GFP, and then visualized in high resolution.
The main principles of confocal microscopy are that a sample is excited with light by focusing a
laser through confocal pinholes and then light emitted back from the excited sample is collected. To
excite the sample, the light from the laser passes through the objective and hits the focal point on the
sample. After the sample is excited, fluorescence emitted from the specimen then passes back through a
dichromatic mirror and is focused on the pinhole aperture [32]. The fluorescence emission from points
above and below the objective focal plane does not contribute to the image because only a small portion
of this emission is delivered through the pinhole aperture [32]. To capture images at different depths of a
sample, the laser is focused at a different depth and the emission from that focal plane are captured.
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Conclusion
After reviewing the current literature, experimental methods can be constructed to properly
validate the injectable 3D fibrin ECM tumor culture model and determine how accurately the tumors
respond to the drug treatment when cultured in a microfluidic device. For all tumor culture models,
ranging from the 2D viability model to the microfluidic device, the tumor cultures were reported to
decrease in size and had reduced proliferation when treated with 5-FU. For the four experiments
discussed in the methods, the results after the statistical analysis were compared to the results from the
literature to determine if it was viable to continue on to the next experiment.
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Chapter 2
METHODS
SW620 Culture and Expansion
A total of four overarching experiments were conducted to determine whether it was possible to
study the drug response of a colorectal tumor culture accurately in a microfluidic device. The first
experiment was a viability assay conducted on small cell cultures in a 96 well plate. After incubation, the
cell culture was introduced to a reagent that would react with the ATP byproducts from the cell culture
and provide a luminescent reading when analyzed with a spectrophotometer. The main purpose of this
experiment was to narrow in on a range of drug concentrations and cell densities where the response
would be linear. The second experiment was scaling the culture up from a 96 well plate to a chamber slide
with a 2D ECM hydrogel. The main purpose of this experiment was to determine if the tumor culture
would react similarly to the drug as the reaction from the cultures in the 96 well plate. The third
experiment was to culture the tumors inside the hydrogel, effectively creating a 3D culture, instead of just
on the surface of the hydrogel. The purpose of this experiment was to determine if the tumor culture
would respond as expected to the drug treatment in the hydrogel, and to narrow in on a range of cell
densities to create a linear response to the drug. The final experiment was taking the cell culture densities
from the 3D experiment, and plating the cells in a hydrogel inside a microfluidic device instead of a
chamber slide. The purpose of this experiment was a proof of concept to show that the microfluidic
device could host a tumor culture and that the tumors would respond as expected to the drug treatment.
All of the SW620 cells used throughout these experiments started as pass 0 and then were
expanded in an RPMI growth media using the recipe found in Appendix A. To make the complete RPMI
media, the RPMI base media, fetal bovine serum (FBS), Penicillin and Streptomycin (P/S), and Fungizone
were combined in a media filter. The media filter was connected to the aspirator and the filtered solution
could now be stored in the refrigerator for future use.
To plate the SW620 cells in the T-75 flasks a cryovial with SW620 cells was thawed and then
pipetted into the T-75 flask with 11mL of complete RPMI media. The working volume of the flasks used
are 12mL and the cells are stored in 1mL of freezing media. The plated flask would then be put in the
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incubator at 37⁰C and 5% C02. The full plating procedure can be found in Appendix B. To expand the cells
after they are plated, the confluent T-75 flask is removed from the incubator and put in the BSC.
Confluency is measured by the percent of the flask that is covered in cells. Flasks that are above 50%
confluency can be expanded. The media is then aspirated off of the flask and Dulbecco’s Phosphate Buffer
Solution (DPBS) is added to clean rinse the cells and their extracellular matrix from the proteins in the
media. Once the cells have been rinsed, the DPBS can be aspirated and Trypsin is added to break down
the proteins in the extracellular matrix so that the cells can be released from the flask surface. Once the
cells are free, an equal volume of complete RPMI media is added to the Trypsin is added to neutralize it.
The resulting cell solution is then split equally into new flasks. The expansions completed across the
experiments were done at a ratio of 1:2 which means that the cells would be split from one flask and
plated into two new flasks. The new flasks are then put back into the incubator at 37⁰C and 5% C02. Media
changes would be performed every 48 hours which involved aspirated the old media and replacing it with
new complete RPMI. The full expansion protocol can be found in Appendix C.
Once an experiment was completed, or after an expansion, the cells would be frozen and placed
back into the liquid nitrogen Dewar. To freeze the cells, the media was aspirated and the cells were rinsed
with DPBS. After aspirating the DPBS, Trypsin would be added to remove the cells from the flask surface.
Once the cells were free in the media, complete RPMI was added to neutralize the trypsin and the
resulting cell solution was transferred to a 50mL conical to be centrifuged. After centrifugation, the
resulting supernatant would be aspirated and the pellet would be resuspended in a freezing media
consisting of complete RPMI, FBS, and Dimethyl Sulfoxide (DMSO). The DMSO protects the cells from
crystalizing as they reach freezing temperatures. After the cells are resuspended in the freezing media,
they are transferred into cryovial tubes and placed in a container with Isopropyl alcohol (IPA) and stored
at -80⁰C for 24 hours. After 24 hours the cells are transferred into liquid nitrogen for long term storage.
The full freezing protocol can be found in Appendix D.
Before running an experiment, the total number of cells needed to run that experiment would be
calculated so that they could be obtained from the cell culture. To count the cells in the cell culture, the
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flask would have its media aspirated and would then be rinsed with DPBS. After the DPBS is aspirated,
Trypsin would be added to the flask to release the cells from the flask surface. Media would then be
added to neutralize the Trypsin. A small volume of the resulting cell solution would then be transferred to
a Eppendorf tube and mixed with Trypan Blue. Trypan Blue is a cell dye that can penetrate the cell wall of
dead cells, turning the cell blue. Under a microscope, the number of cells that are alive (not stained) can
be counted and that number is then extrapolated to get an estimate for the total number of cells in the
culture. The full cell counting protocol can be found in Appendix E.
SW620 Viability Assay
The first experiment conducted was a viability assay performed on SW620 cells cultured in a 96
well plate for 96 hours. The SW620 cell culture used in this experiment was expanded using the Expansion
protocols mentioned above. After counting the cells, there were 28 million cells and only 735,000 were
needed. There were 3 cell densities and 3 drug concentrations tested making 9 experimental treatment
groups and 3 control groups (one for each cell density). The 96 well plate was set up with all the
experimental and control groups as shown in Figure 2.

Figure 2: Viability Assay Experimental Layout. Layout of where the experimental and control groups were
cultured in the 96 well plates for all viability experiments.
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In order to properly gauge viability using the Promega CellTiter-Glo Assay, a serial ATP dilution
needed to be used as a baseline for the spectrophotometer. The ATP serial dilution was created by
starting with a 10mM ATP solution and doing a series of tenfold dilutions to get the required molarities of
1µM, 100nM, and 10nM. The ATP dilution was used to create a standard curve with the
spectrophotometer to make sure the equipment was calibrated correctly. The full ATP serial dilution
protocol can be found in Appendix F.
Once the SW620 cells were counted using the Counting protocol mentioned above, the cell
solution was split into three 15mL conicals so that there would be (15x103 cells *30 wells), (7.5x103 cells
*30 wells), (3.75x103 cells *30 wells) into each conical, respectively. To set the conicals up, the volume of
cell solution needed to reach the cell count for each conical and was transferred from the original cell
solution and added to 3mL of complete RPMI. The three conicals had enough cells and media to fill 30
wells with their respective cell density in 100µL of complete RPMI. The calculations were done for 30
wells because each cell density would have 24 experimental wells and 4 control wells to plate. Two
additional wells were accounted for to mitigate pipetting errors resulting in air bubbles. 100µL of each cell
solution was pipetted into its respective wells. Once the 96 well plate was successfully plated with cells, it
was transferred into an incubator at 37⁰C and 5% C02 for 48 hours.
After the cells had cultured for 48 hours, the 5-Fluorouracil (5-FU) solution was added to the
experimental wells. The drug solution used was made by calculating the amount in grams of 5-FU needed
across the entire 96 well plate and then dissolving the 5-FU in DMSO at a ratio of 53mg 5-FU per every
1mL of Dimethyl Sulfoxide (DMSO). The main drug solution was then split into three 15mL conicals with
2.4mL of complete RMPI so that each conical could have 48mg, 24mg, and 12mg of 5-FU respectively. The
5-FU dosage for these conicals was calculated by multiplying the drug concentration in the experimental
groups (20µg/µL, 10µg/µL, and 5µg/µL) by the number of wells in each group. Once the drug solution and
complete RPMI was combined in each conical, 100µL of that solution was pipetted into its respective
wells. Before adding the drug solution to the 96 well plate, all the experimental wells had their media
aspirated. The control wells also had their media aspirated and 100µL of complete RPMI was pipetted into
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the control wells. The 96 well plate was then transferred into an incubator at 37⁰C and 5% C02 for 48
hours.
After the cells had been exposed to the drug solution for 48 hours, the 96 well plate was ready to
be prepped for the spectrophotometer analysis. First, the CellTiter-Glo Assay reagents needed to be
prepared by thawing the CellTiter-Glo Buffer and then equilibrating the buffer and the CellTiter-Glo
Substrate to room temperature. Once both reagents are room temperature, they can be mixed together
to create the CellTiter-Glo reagent used for the viability assay. The full procedure for creating the
CellTiter-Glo reagent can be found in Appendix G.
Once the CellTiter-Glo reagent was made, the reagent and the 96 well plate were left out for 30
minutes to equilibrate to room temperature. Once at room temperature, 100µL of the reagent into each
well. Because the reagent is light sensitive, the well plate was wrapped in tinfoil after adding the reagent
to the wells. The well plate was then placed on an orbital shaker and gently mixed for 2 minutes. Once the
contents were mixed, the well plate incubated at room temperature for 10 minutes so that the
luminescent signal could stabilize. The well plate was then transferred to a Styrofoam box and taken to
the spectrophotometer. The spectrophotometer analysis of the well plate provides a luminescent reading
for each well where a higher value represents more cell activity, or higher cell viability. The analysis also
provided a standardized curve using the ATP dilution where the luminescent readings had lower values as
the ATP solution was more diluted. These results were then uploaded into Minitab, a statistical analysis
software, to perform analysis of variance testing on the mean absorbance values. First, the descriptive
statistics of the data were taken which would show the average values for each experimental condition,
along with the standard deviation within each group and the minimum and maximum values of each
group. Then, a general linear regression model was built with the data with the intention of using the
model for Tukey pairwise comparisons and to create factorial plots. The Tukey pairwise comparisons
would take into account the sample size, standard deviation, and mean values for each experimental
group and determine whether one group had a significantly different mean from the other groups. The
factorial plots would then provide line graphs showing the data between the experimental groups as a
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way to predict an experimental outcome. The alpha value used for all statistical tests was .95, indicating a
95% confidence in the statistical outcome.
ImageJ Macro Analysis
Two separate macros were written for use with the ImageJ analysis software. The macros were
used to analyze the images taken from the confocal microscope of the 2D gel experiment and the 3D gel
experiment. Both the macro used for the 2D experiment and the macro used for the 3D experiment can
be found in the Appendix. The macro for the 2D experiment would process the images by first setting the
scale to properly reflect the area captured by the microscope. After the scale is set, the macro would add
a Gaussian Blur filter to the image. The Gaussian Blur was implemented to blur the cells as a way to
differentiate between tumors. If the cells were distanced close to other cells, the blur would cause those
cells to be analyzed as a tumor. Next, a color threshold process would run to change to fluorescent green
cells to show as white and to change the background to show as black. This was done by selecting a color
threshold that would capture all shades of green that the cells expressed and would change it to the same
white color value. Similarly, any pixel that wasn’t identified as cell would be changed to the same black
color value. After the color thresholding finished, the parameters in which the measurements would be
taken could be selected. The tumors were fit to an ellipse model and the area, major and minor radii, and
area fraction of the tumors for each image were gathered. The macro then found all particles in the image
larger than 1000µm2 and considered them as tumors. This would output a data table for each tumor
found throughout every image taken from the confocal. The data could then be analyzed with MiniTab.
The complete macro can be seen in Appendix K and the results of the image processing can be seen in
Figure 3.
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Figure 3: 2D Macro Results. The step-by-step results of taking a raw image and processing the image
using the 2D macro. Image 1 is the raw image which starts as an RGB color format. Image 2 shows the
results after the Gaussian Blur filter is applied. Image 3 shows the results after the color thresholding is
applied. And Image 4 is the output of the macro, which outlines and numbers the tumors analyzed and
provides the area of each tumor in a spreadsheet.
The second macro was used for the 3D experiment and functions very similarly to the first
macro. The macro for the 3D experiment would set the image scale to properly reflect the area captured
by the microscope. After the scale is set, it would add all of the z-stack slices together to produce one
image with the fluorescence of the slices summed. Then the macro would apply a Gaussian Blur filter so
that the tumor clumps could be more easily defined. After the filter, the image would be converted to an
8-bit image. The macro would then use an auto threshold to apply a Huang black and white threshold to
the image to make the cells appear white and the background appear black. The difference in threshold
method between the two macros is because the z-stack images were grayscale from the microscope
whereas the images analyzed in the 2D experiment were in color. Like the previous macro, the tumors
were then fit to an ellipse model and the same measurement parameters were inputted. The macro then
found all particles larger than 500µm2 and considered them as tumors. A data table would be generated
showing the measurements for each tumor. This data could then be analyzed for statistical relevance in
MiniTab. The full macro can be found in Appendix L and the results of the image processing can be seen in
Figure 4.
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Figure 4: 3D Macro Results. The step-by-step results of taking a raw image and processing the image
using the 3D macro. Image 1 is the raw image which starts as a 32 bit format. Image 2 shows the results
after the Gaussian Blur filter is applied. Image 3 shows the results after the thresholding is applied. And
Image 4 is the output of the macro, which outlines and numbers the tumors analyzed and provides the
area of each tumor in a spreadsheet.
To validate the two macros, the results from the macro processing were compared to the results
when the images were processed manually. The main difference between the two steps, is the manual
processing involves tracing each tumor in the ImageJ software and recording the area of the geometry
that was traced. The tumors were traced manually by using the polygon selection tool in ImageJ to trace
around the rough geometry of each tumor. Ten tumors from each experiment were used to calculate the
percent error for the macros. To calculate the percent error of the macro, the area value recorded from
the macro was subtracted from the area value recorded manually. The difference was then divided by the
area value recorded manually. An example of a manually calculated tumor area can be seen in Figure 5.
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Figure 5: Macro Validation. The image on the left is a preprocessed image with a tumor manually outlined
(shown with the arrow). The polygon selection tool allows the tumor perimeter to be traced. The image
on the right is the output from the macro. The arrows both point to the same tumor in each image.
Confocal Imaging
All the confocal images taken to analyze the results of these experiments were taken on an
Olympus FV1000 confocal microscope and the Olympus Fluoview 10 software. The laser used to excite the
samples was made Spectra Physics Tsunami laser. Brightfield images could be taken with the confocal
microscope using an arc lamp. All the cells were transfected to express a fluorescent protein known as
Green Fluorescent Protein (GFP) which under the Calcium-Green 1 filter appear green through the
confocal lens. GFP has an excitation peak centered at about 488nm with an emission peak wavelength of
509nm. The samples for all 2D and 3D experiments were imaged using an HV (high voltage) value of 350V,
a gain of 1X, and a 10% offset with a 20X objective lens. The fluorescent channel used the Calcium-green 1
filter to capture the cells. The devices for the microfluidic device experiment were imaged using the
confocal microscope with a HV value of 605V, gain of 1X, 10% output, and a 20X objective lens. The
images for the 2D ECM experiment were 512x512 pixels and were an RGB image type. The images for the
3D ECM experiment were 512x512 pixels and were a 16 bit image type.
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There were three different imaging techniques used with the confocal microscope across the
hydrogel experiments. To image the 2D sample, three images on the same plane as the top of the gel
were taken of each sample. These images represented a 2D slice of the sample where the cells interfaced
with the hydrogel. To image the 3D sample, three z-stacks were taken of each sample. The z-stack images
represented a 3D volume of the sample with 3D tumors in the hydrogel. The ImageJ image processing
software was then used to layer the individual slices together to have the 3D area represented by a single
image. The resultant single image contains a summation of all fluorescence from each slice. So, the
brighter the fluorescence in the image, the more cell activity was present in that location. The advantage
of combining the slices into one image is that it creates an image the represents all the tumors in the focal
area regardless of the depth of the tumor in the sample. This allows all the tumors to be analyzed using
the one representative image. The downside to this method is if two tumors are in the same location but
at different depths, one of the tumors won’t be accounted for in the representative image.
Statistical Analysis
The statistical analysis process for all four experiments followed the same guidelines. First, the
data was input into Minitab by separating the two factors (cell density, drug concentration) and
separating the response (absorbance, tumor size, total area, total count). By doing this, a proper general
linear regression model can be constructed using two factors and three levels. The two factors were cell
density and drug concentration and the three levels were the three different cell densities tested and the
three different drug concentrations tested. In the cell viability experiment, the three drug concentrations
didn’t include the control and instead included the three different 5-FU treatment concentrations. For the
other three experiments, the control (concentration of 0µg/µL) was included as one of the three levels.
The general linear model (GLM) calculates a p-value for each factor based on how that factor affected the
tumor response. For the GLM, the interaction between the two factors was also considered. If the p-value
was less than .05, the factor had a significant impact on the tumor response. When it was confirmed that
the factors had less than a .05 p-value, a Tukey post hoc comparison test could be conducted on the data.
This test calculates the average mean response for each cell density and drug concentration separately
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and then provides the average mean for each interaction (a specific combination of a tested cell density
and drug concentration). The Tukey comparison then compares each mean against the other means and
puts them into groupings. Means within the same grouping are not considered to be significantly different
from one another whereas means in different groupings are significantly different. This is important when
comparing results within the same cell density because it shows whether the drug had a significant effect
on the tumor response.
2-Dimensional SW620 Culture in Fibrin ECM
The second experiment conducted was a 2-Dimensional SW620 culture grown on the top surface
of a Fibrin ECM gel plated in an 8 well chamber slide. The gels were plated in each well of the chamber
slides by mixing the gel solution in Eppendorf tubes than pipetting the solution into the chamber slide
wells to cure. First, the Eppendorf tubes were autoclaved to sterilize them. Next, the fibrinogen solution
was made by adding fibrinogen into Human Endothelial Growth Media (EGM). After the two reagents
were mixed, the solution was aliquoted into the Eppendorf tubes. To start the gel formation process,
thrombin was added to the fibrinogen solution to create the fibrin gel. Because the fibrinogen and
thrombin crosslink quickly at room temperature, the reagents were kept cool and the pipetting process
was done quickly. Once the fibrin gel was pipetted into the chamber slide wells, the chamber slides were
put in the incubator at 37⁰C and 5% C02 to cure for 30 minutes. The full gel plating protocol can be found
in Appendix H.
Because the surface volume of the gels is larger than the surface volume in the 96 well plates,
the cell densities in this experiment were increased from the viability assay experiment. The new
experimental densities were 60x103, 30x103, and 15x103. Additionally, after seeing that the 20µg/µL drug
dosage killed all the cells, the drug concentrations were changed to 10µg/µL, 5µg/µL, and 2.5µg/µL. The
cell densities were established in three 15mL conicals using the same procedures described in the first
experiment above. Once the cell densities were properly established in the conicals, the chamber slides
were transferred from the incubator to the BSC. To plate the cells onto the gels, 250µL of cell solution was
pipetted from the cells to their respective wells as described in Figure 6. Each well would have the desired
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number of cells in 300µL of complete RPMI media. After the cells were plated, the chamber slides were
transferred back to the incubator at 37⁰C and 5% C02 for 48 hours.

Figure 6: 2D ECM Experiment Layout. Layout of where the experimental and control groups were
cultured in the 8 well chamber slides for all 2D ECM gel experiments. There were 4 chamber slides used
for each experimental trial.
After the cells had incubated for 48 hours, the chamber slides were transferred into the BSC so
that the drug solution could be added. The drug solution was made by dissolving 43.75mg of 5-FU into
830uL of DMSO and then splitting the drug solution evenly across three 15mL conicals so that each conical
contained 10µg/µL, 5µg/µL, and 2.5µg/µL respectively. 2.5mL of complete RPMI was added to each
conical to provide each well with 250µL of complete RPMI and the required drug concentration. Once the
drug solution was ready, the old media was aspirated out of the experimental wells and the drug and
media solution was added to the assigned wells in Figure 3. The control wells also had their old media
aspirated and then 250µL of fresh complete RPMI was added to each control well. The chamber slides
were then put back into the incubator at 37⁰C and 5% C02 for 48 hours.
After the cells had been treated with the 5-FU for 48 hours, the samples in the chamber slides
needed to be fixed so they could be properly imaged. To fix the samples, the chamber slides were brought
into the fume hood and the media was aspirated off of every well. After the media is aspirated, 4%
paraformaldehyde (PFA) is added to each well and is left to sit. The PFA fixes the sample by terminating
the cells at their current state. Once the cells are fixed, the PFA is aspirated and replaced with DPBS to
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keep the samples from dehydrating in storage. The chamber slides are then put in a tinfoil wrapped
container to prevent them from getting light contaminated and then stored in the refrigerator. The full
fixing protocol can be found in Appendix I.
To fix the samples, the chamber slides were brought into the fume hood and the media was
aspirated off each well. Then, an equal amount of 4% PFA (paraformaldehyde) as the media aspirated was
added to the wells. After 10 minutes, the PFA was aspirated and an equal amount of DPBS as the media
aspirated was added to each well. The chamber slides were then moved to an empty micropipette tip box
for storage and the box was wrapped in tinfoil because the samples are light sensitive.
Once the samples were ready to be imaged, they were imaged according to the methods
explained in the confocal imaging section above. Three images were taken of each well at random
locations and then the images were analyzed using a custom-made macro for ImageJ which can be found
in Appendix K. The macro would take each image, apply a Gaussian Blur, change the image to 8-bit and
apply a Huang black and white color threshold. Once the image was processed, the macro would call on
the analyze particle function in ImageJ to fit the tumors to an ellipse and calculate the area of the tumors.
Once all the images were analyzed, the results were imported into MiniTab so that the statistical
relevance between drug concentration and tumor size could be determined.
3-Dimensional SW620 Culture in Fibrin ECM
The third experiment conducted is similar to the second experiment, however, the SW620 cells
were grown in the gel instead of on the gel. By adding the cell solution to the fibrinogen solution, a 3D cell
culture was able to be achieved. The fibrin gels used in this experiment were made using a similar method
as the gels made in the 2D experiment. The fibrinogen solution and thrombin were mixed in sterilized
Eppendorf tubes and then pipetted into the chamber slide wells. Because this experiment used a 3D cell
culture, the cell solution had to be mixed in with the fibrinogen solution instead of plating the cells on the
gel. To make the cell and fibrinogen solution, three 15mL conicals were established with the different cell
densities to be used in the experiment. After the appropriate number of cells were in each conical, they
were centrifuged and the media was aspirated off the pellet. The fibrinogen solution was then added to
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each of the three 15mL conicals to resuspend the pellet in the fibrinogen solution. Then the cell and
fibrinogen solution was aliquoted into the Eppendorf tubes and combined with the thrombin to start the
gel formation process. After filling the wells with the mixture, the chamber slides were brought back to
the incubator at 37⁰C and 5% C02 to cure for 30 minutes. The full procedure can be seen in Appendix J.
Because the cells had a 3D volume to grow instead of a flat surface in the previous experiment,
the cell densities used in the experiment were increased to 120x103, 90x103, and 60x103 cells in each gel.
The drug concentrations used in this experiment remained the same at 10µg/µL, 5µg/µL, and 2.5µg/µL.
The experimental groups were set up in the chamber slides and described in Figure 7.

Figure 7: 3D ECM Experiment Layout. Layout of where the experimental and control groups were
cultured in the 8 well chamber slides for all 3D ECM gel experiments. There were 4 chamber slides used
for each experimental trial.
Once the cells had been incubated for 48 hours, the chamber slides were transferred to the BSC
so that the 5-FU could be added to the experimental wells. The drug solution was made by dissolving
57mg of 5-FU into 1.08mL of DMSO and then splitting the drug solution evenly across three 15mL conicals
so that each conical contained 10µg/µL, 5µg/µL, and 2.5µg/µL respectively. 3.3mL of complete RPMI was
added to each conical to provide each well with 300µL of complete RPMI and the required drug
concentration. Once the drug solution was ready, the old media was aspirated out of the experimental
wells and the drug and media solution was added to the assigned wells in Figure 4. The control wells also
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had their media aspirated and replaced with 300µL of fresh complete RPMI. Once the drug was properly
administered, the chamber slides were put back into the incubator at 37⁰C and 5% C02 for 48 hours.
After 48 hours, the chamber slides were transferred to the fume hood so that the samples could
be fixed using the fixing protocol used in the second experiment. Once the samples were ready to be
imaged, they were taken to a confocal microscope for analysis. The samples were imaged using the
settings and methods mentioned in the confocal imaging section above. The fluorescent channel used the
Calcium-green 1 filter to capture the cells. Because the cells were in a 3D culture, the confocal microscope
took slices on the z-axis at each location to create z-stack images. These images spanned 25µm in depth.
Three z-stack images were taken of each well at random locations and analyzed using a different ImageJ
macro which is found in Appendix L. The new macro does all the same processing as the macro used in
the second experiment but before the image processing, the z-stack slices were summed into one picture.
3-Dimensional SW620 Culture in a Microfluidic Device
The fourth experiment conducted was to take the cell culture in a fibrinogen gel and plate it
inside a microfluidic device with constant media perfusion through the chamber of the device. This
experiment uses the same culture conditions as the 3D gel experiment but instead of having stagnant
media above the gel, the media is constantly moving around the gel in the microfluidic device. There were
two device designs used in this experiment which can be seen in Figure 8. One of the device designs used
was a single chamber device with an ECM inlet and outlet on either end of the chamber and a media inlet
and outlet at the top and bottom of the chamber. The other device design used was a dual chamber
design with an ECM inlet going into the first chamber, a connection from the first chamber to the second
chamber, and then an ECM outlet out of the second chamber. There were also a media inlet and outlet
system where each chamber had openings on the top and bottom which led to the main media inlet and
outlet system.
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Figure 8: Microfluidic Device Schematic. A schematic of the device used to culture the tumors. The cells
were cultured in the 10µL volume of the main chamber.
Because the media in the experiment was being delivered through the ECM inlet instead of the
media perfusion inlet, the media perfusion inlet and outlet were plugged after the devices were primed.
The plugs were made by cutting small pieces of tubing and cauterizing one end. Before the experiment,
the plugs, devices, and Eppendorf tubes were put in an autoclave pouch and sterilized for 30 minutes at
110⁰C. After they were heated at temperature, they were left to dry in the autoclave for 30 minutes.
While the devices were being sterilized, cells were counted using the cell counting procedure and then a
fibrinogen and cell solution media was made using the same procedure described in the previous
experiment. Each of the 80µL aliquots of fibrinogen and cell solution was made so that it would have
240,000 cells. Once the devices were out of the autoclave, they were brought to the BSC so that they
could be primed. The priming process included running complete RPMI through the media inlet and ECM
inlet so that there wouldn’t be any air bubbles in the device. After the device was primed, a plug was put
in the media inlet and outlet and an empty 200µL micropipette tip was placed in the ECM outlet. 4µL of
thrombin was then added to an 80µL aliquot but a 200µL micropipette tip was used to add 20uL of the
fibrin and cell solution into the ECM inlet of the device. Once the solution reached the outlet, the pipette
tip was removed from the pipette and the two 200µL tips remained in the device until the ECM cured. To
cure the ECM in the device, the device was transferred from the BSC to the incubator at 37⁰C and 5% C02
for 5 minutes. Once the ECM was cured, both 200µL micropipette tips were removed and a new 200µL
micropipette tip was placed in the ECM outlet. Then, 75µL of complete RPMI was gently pipetted through
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the ECM inlet using another 200µL micropipette tip. Once the media reached the ECM outlet and starting
going into the 200µL micropipette tip in the ECM outlet, the 200µL micropipette with the remaining
media was removed from the pipette and left in the ECM inlet. The cells were now ready to be cultured in
the device and the device was placed in the incubator at 37⁰C and 5% C02 for 48 hours.
After the cells had been incubated for 48 hours, the devices were transferred to the BSC so that
the 5-FU could be administered. The drug solution was made using the same protocol as in experiment 3
but only the 5µg/µL and 2.5µg/µL concentrations were tested. Once the appropriate amount the drug
solution was mixed into the complete RPMI media, it was ready to be put in the device. To administer the
drug solution, both the 200µL micropipette tips in the ECM inlet and outlet were removed. A new 200µL
micropipette tip was placed in the ECM outlet. Then, an 200µL micropipette tip was used to put 75µL of
the complete RPMI with the corresponding drug concentration into the ECM inlet. Once the media
reached the ECM outlet and starting filling the 200µL micropipette tip in the ECM outlet, the 200µL
micropipette tip with the remaining media was removed from the pipette and left in the ECM inlet. After
the drug solution had been delivered, the device was brought back to the incubator at 37⁰C and 5% C02
for 48 hours.
Once the cells had been exposed to the 5-FU for 48 hours, the device was transferred to the
fume hood to fix the sample. Both 200µL micropipette tips were removed from the device and a new
200µL micropipette tip was placed in the ECM outlet, then 75µL of 4% PFA was pipetted through the ECM
inlet with a 200µL micropipette tip. Once the PFA had reached the ECM outlet and started to fill the 200µL
micropipette tip in the ECM outlet, the device was left to sit for 10 minutes for the PFA to fix the cells.
After the 10 minutes, both 200µL micropipette tips were removed and a new 200µL micropipette tip was
placed in the ECM outlet. Then, 75µL of DPBS was pipetted into the ECM inlet using a 200µL micropipette
tip. Once the DPBS had reached the ECM outlet and started to fill the 200µL micropipette tip in the ECM
outlet, both 200µL micropipette tips were removed and the device was placed in an empty micropipette
tip box for storage. The box was wrapped in tinfoil before being stored in the refrigerator.
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The images were captured using the settings and methods explained in the confocal imaging
section above. The brightfield light was used to find the device geometry and then the Calcium-green 1
filter was used to image the cells. The FV-10 software was used to take images across the device and then
stitch the images together to create an image capture of the entire cell culture area in the device. Each
image would capture an area in the device of 636.4µm x 636.4µm and the stitched image would have a
total area of 6597.64µm x 2301.96µm with the images being stitched together in a 4x12 orientation.
There would be overlap between images but so the stitched dimensions are slightly smaller than the total
area captured. At each image location, 20 slices were taken to cover a 25µm depth. The images where
then brought into ImageJ to sum the slices and process the image. The area of each tumor was calculated
and the data was imported into MiniTab to run statistical analysis. The goal of this experiment was to
determine if the cell response to the 5-FU would be similar in the device as it was in the chamber slide.
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Chapter 3
RESULTS
Cell Viability Assay
To properly calibrate the spectrophotometer and validate the plate readings, three ATP
molarities were established in the well plate prior to reading. The ATP was serial diluted to 1µm, 100nM,
and 10nM and the absorbance values should result in a linear line. The ATP calibration curve can be seen
in Figure 9. The average absorbance values from the ATP dilutions were 2460.433, 947.9467, and
422.2133 for the 1µm, 100nM, and 10nM molarities respectively. A scatterplot was created with the three
values and the regression line was calculated to determine the validity of the standard curve. The R 2
value, which equates to how well the points fit the regression line, for the standard curve was .9154 or
91.54%.
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Figure 9: ATP Standard Curve. A scatter plot of the ATP serial dilution absorbance values to validate the
spectrophotometer results. The x-axis shows the three molarity values achieved by the serial dilution and
the y-axis is the absorbance reading from the spectrophotometer. The linear regression line can be seen
and it has a R2 value of .9154. Each dot on the same vertical axis represents results from the same
molarity.
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The first set of data is for the absorbance values recorded for the 15,000 initial cell density
groups. Averages for these experimental conditions can be seen in Table 1. The baseline value is given by
the absorbance reading from a well with only complete RPMI media and no cells. This means that
absorbance values that are similar to the baseline value indicate very little cell activity in the well. Figure
10 shows the averages across the replicates compared to each other rather than showing the individual
values for each replicate. It is easier to see the statistical difference across the averages using the bar
chart in Figure 10. The general ANOVA results from this data set, seen in Appendix M, showed that each
average was significantly different than the other averages.

Table 1: Viability Assay Experiment Average Absorbance on 15,000 Cells .
Drug Concentration (µg/µL)
Control (0µg/µL)
5
10
20
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Average Absorbance
1126.26 ± 137.73
692.22 ± 158.38
490.56 ± 157.53
238.37 ± 13.29
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Figure 10: Average Absorbance for 15,000 Cells. A bar chart depicting the average values across the 8
replicates for each experimental condition that had an initial plating density of 15,000 cells per well. The
gray, vertical scale on the bar for the experimental groups shows the standard deviation across the 8
replicates. The asterisk above each bar represents that the average shown is significantly different than all
other averages.
The next set of data recorded was for the 7,500 initial cell density experimental groups. A
summary of the data can be seen in Table 2. The full statistical analysis for the 7,500 cell plating density
groups can be found in Appendix M.
Table 2: Viability Assay Experiment Average Absorbance on 7,500 Cells.
Drug Concentration (µg/µL)

Average Absorbance

Control (0µg/µL)

888.35 ± 49.52

5

524.66 ± 53.53

10

469.63 ± 26.63

20

235.76 ± 9.71

The trend in the data can be visualized by the bar chart in Figure 11. After a general ANOVA
statistical analysis was completed on the experimental group averages, it was concluded that each
average was statistically different from each other.
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Figure 11: Average Absorbance for 7,500 Cells. A bar chart depicting the average values across the 8
replicates for each experimental condition that had an initial plating density of 7,500 cells per well. The
gray, vertical scale on the bar for the experimental groups shows the standard deviation across the 8
replicates. The asterisk above each bar represents that the average shown is significantly different than all
other averages. The double asterisk above the two bars represent that they are significantly different
from all other averages but not significantly different from each other.
The next set of data recorded was for the 3,750 initial cell density experimental groups. A
summary of the data can be seen in Table 3.
Table 3: Viability Assay Experiment Average Absorbance on 3,750 Cells .
Drug Concentration (µg/µL)

Average Absorbance

Control (0µg/µL)

766.620± 42.24

5

330.73 ± 41.77

10

324.68 ± 19.59

20

238.74 ± 10.59

The trend in the data can be visualized by the bar chart in Figure 12. After the statistical analysis
found in Appendix M, it was concluded that the averages for the 3,750 initial cell density were statistically
different after treatment.
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Average Absorbance for 3,750 Cells
900

*

800

700

Absorbance

600
500
400
300
200
100

0
Baseline

20 ug/uL

10 ug/uL

5 ug/uL

Control

Drug Treatment

Figure 12: Average Absorbance for 3,750 Cells. A bar chart depicting the average values across the 8
replicates for each experimental condition that had an initial plating density of 3,750 cells per well. The
gray, vertical scale on the bar for the experimental groups shows the standard deviation across the 8
replicates. The asterisk above each bar represents that the average shown is significantly different than all
other averages.
A general linear model was run using Minitab to produce an analysis of variance for the cell
density, drug concentration, and the interaction between the cell density and drug concentration. A
summary of the P-values can be seen in Table 4. A P-value describes the probability that the observed
response happened by chance. The very low P-values for the cell density, drug concentration, and the
interaction mean that all three had a significant impact on the cell response to the drug. These ANOVA
results can be seen in Appendix N.
Table 4: Viability Assay Experiment P-values.

Factor

P-Value

Cell Density

4x10-9

Drug Concentration

2x10-16

Interaction

3.7x10-6
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Additionally, Tukey pairwise comparisons were fun for the cell density groups and the drug
concentration groups. A Tukey pairwise comparison tests every pair of all groups to determine if there is a
difference between the mean, or average, values of all pairs using a studentized range of distribution. The
results of these comparisons can be found in Appendix O. A summary of the Tukey means for cell density
and drug concentration can be seen in Tables 5 and 6 respectively.
Table 5: Viability Assay Experiment Tukey Comparison for Cell Density .
Cell Density (cells/well)

Mean Absorbance

15,000

473.715

7,500

410.016

3,750

298.052

Table 6: Viability Assay Experiment Tukey Comparison for Drug Concentration .
Drug Concentration (µg/µL)

Mean Absorbance

20

515.867

10

428.291

5

237.624

For the Tukey comparison of the interaction groups, the highest mean absorbance was with the
15,000 cells treated with 5µg/µL of 5-FU and the absorbance value was 692.215. This treatment group
was in a separate grouping than the other experimental groups. The second highest absorbance grouping
had the 15,000 cells treated with 10µg/µL 5-FU, the 7,500 cells treated with 10µg/µL 5-FU, and the 7,500
cells treated with 5µg/µL 5-FU. The last grouping had the lowest mean absorbance values and consisted
of the rest of the experimental groups. Factorial plots were then created in Minitab to depict the effect of
the interaction between cell density and drug concentration. The full Tukey pairwise comparison can be
found in Appendix O. A main effects plot, which summarizes the data from the Tukey pairwise
comparisons can also be seen in Appendix 0.
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Because this was the first experiment run, the sample size of replicates needed for a desired
statistical power needed to be calculated. Using Minitab, the number of replicates needed for each
experimental group was calculated using the difference in means and trying to reach a target power of 80
or 90%. The power of a test is the probability of observing a true positive result instead of observing a
result that happened by chance. For a target power of 80%, 7 replicates would have been needed; and for
a target power of 90%, 9 replicates would have been needed. In order to maximize the actual power of
the experiment and still be in the constraints of a 96 well plate, 8 replicates for each experimental group
were used with an actual power of 89.83%. The two power analysis graphs can be found in Appendix P.
Validation of the ImageJ Macros
To validate the accuracy of the macro used for the 2D ECM hydrogel analysis, 10 tumors were
selected randomly throughout the experiment and had the area manually calculated in ImageJ. The value
recorded with the macro was subtracted from the value recorded manually and then that difference was
divided by the manually recorded value. The average percent error for the 2D macro was 6.43 ± 5.98%.
The macro used for the 3D ECM experiment was validated with the same process. The area was calculated
manually after the images were combined into the z-stack. The average percent error for the 3D macro
was 6.58 ± 4.86%. Scatterplots showing the graphical difference between the recorded values for the
manual method and the macro can be seen in Figures 13 and 14 for both the 2D and 3D macros
respectively. The average tumor size measured for the macro and manually along with the standard error
can be seen in Table 7.
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Manual vs 2D Macro Area Values
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Figure 13: Manual vs 2D Macro Area Values. A scatterplot showing each individual value for the manual
vs macro tumor area calculations used to validate the 2D macro. The x-axis shows the area value for the
manual calculations and the y-axis shows the macro calculated tumor area.
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Figure 14: Manual vs 3D Macro Area Values. A scatterplot showing each individual value for the manual
vs macro tumor area calculations used to validate the 3D macro. The x-axis shows the area value for the
manual calculations and the y-axis shows the macro calculated tumor area.
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Table 7: Comparison between Macro and Manual Values in 2D and 3D.
The percent error reported is the average of all percent errors calculated for each individual tumor.
Experiment

Macro

Manual

Percent Error

2D ECM Hydrogel

721.8 ± 185.96 µm2

712.8 ± 187.43 µm2

6.43 ± 5.98%

3D ECM Hydrogel

1598.3 ± 264.86 µm2

1604.9 ± 278.88 µm2

6.58 ± 4.86%

2D ECM Hydrogel Experiment

Figure 15: 2D ECM Experiment Representative Image. Representative images for each of the nine
experimental conditions. From left to right they are organized in ascending cell density and from top to
bottom they are organized in ascending drug concentration. Image 1 is the 7,500 cell control. Image 2 is
the 15,000 cell control. Image 3 is the 30,000 cell control. Image 4 is the 7,500 cell with 5µg/µL 5-FU.
Image 5 is the 15,000 cell with 5µg/µL 5-FU. Image 6 is the 30,000 cell with 5µg/µL 5-FU. Image 7 is the
7,500 cell with 10µg/µL 5-FU. Image 8 is the 15,000 cell with 10µg/µL 5-FU. Image 9 is the 30,000 cell with
10µg/µL 5-FU.
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The first metric analyzed with the 2D tumor cultures was the total tumor area across the
treatment groups. This value was calculated by adding the tumor size of all tumors identified per group. A
bar graph comparing the total tumor areas across the experimental groups can be seen in Figure 16. The
reason there is no data for the 5-FU added to the 7,500 cells is because both drug treatments completely
killed the cell cultures so the total tumor area was zero. Representative images of each experimental
condition can be seen in Figure 15.
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Figure 16: 2D ECM Experiment Total Tumor Area. A bar chart showing the mean value for the total tumor
area across all the treatment groups. The y-axis is the total area in micrometers squared and the x-axis is
each treatment condition. The cell density is noted with the number before the “C” and the drug
concentration is noted with the number before the “D”. A zero before the “D” means it was a control
group for that cell density. The gray, vertical scale on the bar for the experimental groups shows the
standard deviation across all the tumors analyzed in that treatment group. The asterisk above the bars
denotes that the mean for that experimental condition is significantly different than the other means
within the same cell density grouping.

Unlike the 7,500 initial cell condition, all three drug concentrations had enough data points for
each concentration to standard deviation calculations. Once again, the 30,000 initial cell density was large
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enough for enough tumor cells to survive to have standard deviation calculations for all three drug
concentrations.
The next metric that was analyzed was the average number of tumors in each of the
experimental wells in the chamber slides. Once again, the only data depicted in the graphs for the 7,500
initial cell density is the control group. A table summarizing the data for this metric can be seen in Table 9.
A bar chart with the averages compared can be seen in Figure 17. A table summarizing the data points for
the total tumor area can be seen in Appendix AC.

Total Tumor Count
18

*

Tumor Count (tumors/well)

16
14
12
10

*

8
6
4
2
0

10D

5D

15C

0D

10D

5D

0D

10D

5D

0D

7.5C

30C

Treatment

Figure 17: 2D ECM Experiment Total Tumor Count. A bar chart showing the mean value for the total
tumor area across all the treatment groups. The y-axis is the total area in micrometers squared and the xaxis is each treatment condition. The cell density is noted with the number before the “C” and the drug
concentration is noted with the number before the “D”. A zero before the “D” means it was a control
group for that cell density. The gray, vertical scale on the bar for the experimental groups shows the
standard deviation across all the tumors analyzed in that treatment group. The asterisk above the bars
denotes that the mean for that experimental condition is significantly different than the other means
within the same cell density grouping.
Unlike the 7,500 initial cell condition, all three drug concentrations had enough data points for
each concentration to standard deviation calculations. The 30,000 initial cell density groups did not have a
linear trend in average tumor count when comparing drug concentrations.
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The last metric analyzed in this experiment was the average tumor size in each of the wells in the
chamber slide. Similar to the last two metrics, the only data for the 7,500 initial cell density is for the
control groups. A bar chart comparing the average tumor size per well across the experimental groups can
be seen in Figure 18. The descriptive statistics can be seen in Appendix Q. A summary of the data can be
seen in the table in Appendix AC.
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Figure 18: 2D ECM Experiment Average Tumor Size. A bar chart showing the mean value for the average
tumor size across all the treatment groups. The y-axis is the total area in micrometers squared and the xaxis is each treatment condition. The cell density is noted with the number before the “C” and the drug
concentration is noted with the number before the “D”. A zero before the “D” means it was a control
group for that cell density. The gray, vertical scale on the bar for the experimental groups shows the
standard deviation across all the tumors analyzed in that treatment group. The asterisk above the bars
denotes that the mean for that experimental condition is significantly different than the other means
within the same cell density grouping.
Once again, the 15,000 initial cell density was able to produce tumors large enough to survive all
three drug concentrations, allowing for proper standard deviation calculations. The 30,000 initial cell
density had a significantly larger tumor size in the control group when compared to the drug treatment
groups, which is expected.
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Tukey pairwise comparisons were also run for the three metrics tested. The first Tukey
comparison was done for the average tumor size for all the experimental wells. The results of this Tukey
test can be seen in Table 8. The full Tukey comparisons for average tumor area can be seen in Appendix R.
The Tukey comparison for this metric can be seen in Appendix R. Finally, the Tukey comparison for total
tumor area across all the wells can be seen in Appendix R. The factorial plots for all three metrics can also
be seen in Appendix R.
Table 8: 2D Hydrogel Experiment Tukey Comparisons.

Average
Tumor
Size

Total
Tumor
Count

Total
Tumor
Area

Cell Density (cells/well)

Mean Tumor Size (µm2)

30,000

4,145.36

15,000

2,352.74

7,500

1,469.81

Drug Concentration (µg/µL)

Mean Tumor Size (µm2)

0

4,558.61

5

2,160.95

10

1,248.35

Cell Density (cells/well)

Mean Tumor Count

30,000

8.67

15,000

6.08

7,500

2.83

Drug Concentration (µg/µL)

Mean Tumor Count

0

8.70

5

5.67

10

3.21

Cell Density (cells/well)

Mean Total Area (µm2)

30,000

28,935.4

15,000

19,899.8

7,500

403.2

Drug Concentration (µg/µL)

Mean Total Area (µm2)

0

35,657.8

5

9,7670.2

10

3,103.9
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The summary of the general linear model for each metric analyzed can be found in Table 9. The
full general linear models for all the metrics can be seen in Appendix S.
Table 9: 2D Hydrogel Experiment P-values.

Metric

Factor

P-value

Total Tumor Area

Cell Density

7.3x10-3

Drug Concentration

2.0x10-4

Cell Density

9.3x10-2

Drug Concentration

5.1x10-2

Cell Density

3.3x10-3

Drug Concentration

1.7x10-6

Tumor Count

Average Tumor Size

Lastly, a main effects plot was constructed to further breakdown the effect of just cell density or
drug concentration on the cell population. Figure 19 is a line graph that shows the trend within each
factor.

Figure 19: 2D Main Effects Plot for Average Tumor Size. A main effects plot showing the trend within the
cell density factor and the drug concentration factor. The graph on the left is cell density versus tumor
size, and the graph on the right is drug concentration versus tumor size.
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3D ECM Hydrogel Experiment
Similar to the 2D experiment, the metrics used to analyze the 3D results were average tumor
size, average tumor count, and total tumor area. The first metric analyzed with the 3D tumor cultures
was the total tumor area across the treatment groups. This value was calculated by adding the tumor size
of all tumors identified per group. A bar graph comparing the total tumor areas across the experimental
groups can be seen in Figure 21. The full descriptive statistics with a histogram showing every data point
can be found in Appendix Z. Representative images of each experimental condition can be seen in Figure
20.

Figure 20: 3D ECM Experiment Representative Image. Representative images for each of the nine
experimental conditions. From left to right they are organized in ascending cell density and from top to
bottom they are organized in ascending drug concentration. Image 1 is the 60,000 cell control. Image 2 is
the 90,000 cell control. Image 3 is the 120,000 cell control. Image 4 is the 60,000 cell with 2.5µg/µL 5-FU.
Image 5 is the 90,000 cell with 2.5µg/µL 5-FU. Image 6 is the 120,000 cell with 2.5µg/µL 5-FU. Image 7 is
the 60,000 cell with 5µg/µL 5-FU. Image 8 is the 90,000 cell with 5µg/µL 5-FU. Image 9 is the 120,000 cell
with 5µg/µL 5-FU.
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A summary of the data for the total tumor area can be seen in Appendix AD. Unlike the 60,000
initial cell density groups, the 90,000 initial cell density groups didn’t have any density with a significantly
higher total tumor area than the other densities. Similar to the 60,000 initial cell density group, the
2.5µg/µL 5-FU treatment for the 120,000 initial cell density group led to an average total tumor area that
was significantly larger than the tumor areas for the other drug concentrations.

*

*

Figure 21: 3D ECM Experiment Boxplot of Total Tumor Area. A boxplot of the total tumor area across the
three different cell densities (60,000; 90,000; 120,000) and the four different drug concentrations (0, 2.5,
5, 10) in µg/µL. The x-axis separates the three initial cell densities for each drug concentration and the yaxis has the average total tumor area in micrometers squared. The gray line in each box represents the
median tumor size and the area above and below the line are the 3 rd and 1st quartiles respectively. The
lines extending from each box represents the standard deviation of the data. The asterisk denotes the
value is significantly different than all other values within the same cell density group.
The second metric analyzed for the 3D experiments was average tumor count per well. Figure 22
shows a bar chart summarizing the averages across treatments. The full descriptive statistics with a
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histogram showing all the data points can be found in Appendix W. A table summarizing the data can be
seen in Appendix AD.

*

*

Figure 22: 3D ECM Experiment Boxplot of Total Tumor Count. A boxplot of the average tumor count
across the three different cell densities (60,000; 90,000; 120,000) and the four different drug
concentrations (0, 2.5, 5, 10) in µg/µL. The x-axis separates the three initial cell densities for each drug
concentration and the y-axis has the average tumor count. The gray line in each box represents the
median tumor size and the area above and below the line are the 3 rd and 1st quartiles respectively. The
lines extending from each box represents the standard deviation of the data. The asterisk denotes the
value is significantly different than all other values within the same cell density group.

Unlike the 60,000 initial cell density groups, the 90,000 initial cell density groups didn’t have any
density with a significantly higher total tumor area than the other densities. Once again with the 120,000
cell density groups, only the cultures treated with 2.5µg/µL 5-FU had a tumor count average significantly
larger than the other concentrations tested.
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The average tumor size for each of the experimental conditions are summarized in Appendix AD.
Figure 23 shows a bar chart summarizing the averages across treatments. The full descriptive statistics
along with a histogram showing every data point can be seen in Appendix T.

&
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Figure 23: 3D ECM Experiment Boxplot of Average Tumor Size. A boxplot of the average tumor size
across the three different cell densities (60,000; 90,000; 120,000) and the four different drug
concentrations (0, 2.5, 5, 10) in µg/µL. The x-axis separates the three initial cell densities for each drug
concentration and the y-axis has the average tumor size in micrometers squared. The gray line in each box
represents the median tumor size and the area above and below the line are the 3 rd and 1st quartiles
respectively. The lines extending from each box represents the remaining data. The x’s above the boxes
represent outliers in the data. The ampersand denotes the value is significantly different than all other
values within the same cell density group.
Neither the 60,000 nor 90,000 initial cell densities had drug treatments that caused a significant
decrease in average tumor size. However, a trend can be seen where the higher the drug concentration,
the lower the average tumor size. With the 120,000 initial cell density groups, the control had a
significantly higher tumor size than all other conditions, and the 2.5µg/µL 5-FU treatment had a
significantly higher tumor size than the 5µg/µL and 10µg/µL treatments.
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Tukey pairwise comparisons were also run for the three metrics tested. The first Tukey
comparison was done for the average tumor size for all the experimental wells. The results of this Tukey
test can be seen in Table 10. The full Tukey comparisons can be seen in Appendix AB.
Table 10: 3D Hydrogel Experiment Tukey Comparisons.

Total
Tumor
Area

Total
Tumor
Count

Average
Tumor
Size

Cell Density (cells/well)

Total Tumor Area (µm2)

120,000

30,964.7

90,000

22,617.0

60,000

27,341.9

Drug Concentration (µg/µL)

Total Tumor Area (µm2)

0

40,854.2

2.5

45,118.9

5

14,477.5

10

7,447.5

Cell Density (cells/well)

Tumor Count

120,000

32.3

90,000

22.8

60,000

27.5

Drug Concentration (µg/µL)

Tumor Count

0

26.8

2.5

41.8

5

26.9

10

14.7

Cell Density (cells/well)

Average Tumor Size (µm2)

120,000

870.079

90,000

882.922

60,000

968.797

Drug Concentration (µg/µL)

Average Tumor Size (µm2)

0

1516.68

2.5

1083.46

5

537.59

10

491.33
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The summary of the general linear model for each metric analyzed can be found in Table 11. The
full general linear models for all the metrics can be seen in Appendix U for the average tumor size. The
model for the tumor count can be found in Appendix X. And the model for the total tumor area can be
found in Appendix AA.
Table 11: 3D Hydrogel Experiment P-values.

Metric

Total Tumor Area

Tumor Count

Average Tumor Size

Factor

P-value

Cell Density

2.3x10-2

Drug Concentration

0.0

Interaction

1.8x10-2

Cell Density

2.4x10-3

Drug Concentration

1.2x10-12

Interaction

8.1x10-2

Cell Density

9.7x10-2

Drug Concentration

0.0

Interaction

3.3x10-1

3D Fibrin Hydrogel Cultured in Microfluidic Device
The last experiment was to inject the 3D ECM analyzed in the previous experiment into three
microfluidic devices and keep one device as a control, one device treated with 2.5µg/µL of 5-FU, and the
last device treated with 5µg/µL of 5-FU. A representative image of the three device treatments can be
seen in Figure 24.

53

Figure 24: Microfluidic Device Experiment Representative Image. Each image represents one of the
devices and its respective treatment. The pictures are organized top to bottom in ascending drug
concentration. Image 1 is the control device. Image 2 is the 2.5µg/µL 5-FU treatment. Image 3 is the
5µg/µL 5-FU treatment. Each device was seeded with 120,000 cells. The rough outlines of the device are
shown.
Because only three devices were able to be analyzed, the sample size was too small to run
effective analysis of variance statistics. The same three metrics of average tumor size, total tumor area,
and total tumor count were recorded for the control device, the 2.5µg/µL treated device, and the 5µg/µL
treated device. A summary of the results for all three metrics can be seen in Table 12. A bar chart showing
the trend in the tumor response can be seen in Figure 25. The trend in tumor count can be seen in Figure
26, and the trend in the average tumor size can be seen in Figure 27.
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Table 12: Microfluidic Device Experiment Results.
Metric

Total Tumor Area

Tumor Count

Average Tumor Size

Drug Concentration (µg/µL)

Response

0

294,998µm2

2.5

7,814µm2

5

4,683µm2

0

10 Tumors

2.5

5 Tumors

5

5 Tumors

0

29,499.77 ± 55,539µm2

2.5

1,562.873 ± 398µm2

5

936.55 ± 990µm2

Total Tumor Area in Microfluidic Devices
Total Tumor Area (µm2)
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300000

*

250000
200000
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0
0

2.5

5

5-FU Concentration (µg/µL)

Figure 25: Microfluidic Device Experiment Total Tumor Area. A bar chart showing the total tumor area
across all the microfluidic devices (the control, 2.5µg/µL, and 5µg/µL). The y-axis is the total tumor area in
micrometers squared and the x-axis is each treatment condition. A treatment of 0µg/µL 5-FU represents
the control groups. The gray, vertical scale on the bar for the experimental groups shows the standard
deviation across all the tumors analyzed in that treatment group. The asterisk denotes the value is
significantly different than all others.
The total tumor area and tumor was calculated by adding together all the analyzed tumors for
one device and providing a single number representing that device. With the tumor count, the total
number of tumors also provided a single number for each device. Because both metrics only had one
value, or number, for each device, the bar charts don’t have standard deviations shown.
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Tumor Count in Microfluidic Devices
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Tumor Count

12
10
8
6
4
2
0

0

2.5

5

5-FU Concentration (µg/µL)

Figure 26: Microfluidic Device Experiment Total Tumor Count. A bar chart showing the total tumor count
across all the microfluidic devices. The y-axis is the total tumor count and the x-axis is each treatment
condition. A treatment of 0µg/µL 5-FU represents the control groups. The gray, vertical scale on the bar
for the experimental groups shows the standard deviation across all the tumors analyzed in that
treatment group. The asterisk denotes the value is significantly different than all others.
Because the average tumor size metric uses an average in each device instead of just a total
number, the standard deviation values can be shown in the bar chart.

Average Tumor Size in Microfluidic Devices
90000

*

80000

Tumor Area (µm2)
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30000
20000
10000
0
0

2.5

5

5-FU Concentration (µg/µL)

Figure 27: Microfluidic Device Experiment Average Tumor Size. A bar chart showing the average tumor
size across all the microfluidic devices. The y-axis is the average tumor size in micrometers squared and
the x-axis is each treatment condition. A treatment of 0µg/µL 5-FU represents the control groups. The
gray, vertical scale on the bar for the experimental groups shows the standard deviation across all the
tumors analyzed in that treatment group. The asterisk denotes the value is significantly different than all
others.
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Chapter 4
DISCUSSION
Overview of Experiments
The structure of the four experiments completed was a progressive approach to eventually show
a proof of concept that the SW620 tumor cells could be cultured and treated in a fibrin hydrogel that was
injected into a PDMS microfluidic device. The cell viability assay experiment was needed to find the
working range of cell densities and drug concentrations that had a linear response. The reason a linear
response in all the experiments is ideal is because the regression equation can then be used to estimate
the effect of dosage concentrations that weren’t used in the experiments. The 2D ECM experiment was
conducted to narrow down the culture methods for culturing SW620 cells on a fibrin hydrogel and
treating the cells effectively on the fibrin hydrogel. The 3D ECM experiment was conducted to prove that
the SW620 cells could be cultured within the hydrogels and that the 5-FU in the media would perfuse
through the gel and react with the cells. Finally, the last experiment in the microfluidic devices was able to
show that the cells could be cultured in the device, and that the 5-FU and complete RPMI media could be
properly perfused through the device and treat the cells.
Limitations
One of the major limitations in this research was the lack of supply for the microfluidic devices
used. Because of Covid, the lab was shutdown therefore there wasn’t any production for more devices,
only leftover devices from previous experiments could be used. Because there weren’t enough devices to
properly run a two-factor analysis of variance, the tumor response was only analyzed for one cell density
instead of three densities like the other experiments. Because the tumor count and total tumor area
metrics were one data point for each device, there were no standard deviations for the values.
Another limitation of the research is once the cells were cultured with the fibrin gel, a confocal
microscope became the only option for analyzing the results. Instead of using a more sensitive metric, like
the ATPase assay, the tumors were analyzed with image software that isn’t as sensitive as a biological
analysis method. Additionally, with the confocal imaging, not every tumor in each well could be analyzed
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due to the time required to image the entire well. Instead, 3 locations were chosen by random for each
well and if at least three tumors were found at that location then an image would be taken and those
tumors would be analyzed. Over the three replicates for each experimental condition, 9 images per
experimental condition were analyzed.
Another limitation comes with the confocal imaging. Due to the high number of tumors in the
sample images, potentially having tumors unaccounted for in the representative image doesn’t affect the
overall statistical outcome. To image the microfluidic devices, a series of z-stack images were taken to
cover the entirety of the microfluidic device chambers with the cell culture. Each image taken of the
device slightly overlaps with the adjacent images to ensure that the entirety of the device is captured. The
Fluoview imaging software used with the confocal microscope then stitches the images together to create
a single representative image of the device but retaining the same dimensions as if all images taken were
laid next to each other. This process is completed for each z-stack depth and the resulting representative
images are overlayed and have their fluorescence summed to create one image which represents the
entire 3D tumor culture within the device.
Confocal microscopes are limited to the excitation wavelengths available with common lasers
and the high-intensity laser irradiation can be harmful to living cells [32]. Both of these disadvantages
don’t affect the imaging of the SW620 cells in this experiment. The filter used with GFP is within the range
of excitation wavelengths for the microscope, so there is no limitation with the laser. Additionally, the
cells are fixed in paraformaldehyde prior to imaging, meaning the cell samples are fixed and can’t be
further damaged by laser exposure.
Cell Viability Assay
The cell viability experiment was conducted to find a range of cells to initially seed the culture
area so that the tumors would exhibit a linear response to the 5-FU treatment. For the 15,000 initial cell
density, the control wells had the highest cell viability than all other treatment groups, followed by the
5µg/µL treatment which produced the next highest viability. The recorded viability for the 5µg/µL 5-FU
treatment were significantly different from the control group and the 10µg/µL treatment group. The
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10µg/µL treatment group also had cell viability which was significantly different from the 20µg/µL and
5µg/µL treatment groups. The 20µg/µL treatment group reduced the cell viability drastically to the point
where the absorbance reading for the 20µg/µL treatment group wasn’t significantly different from the
baseline absorbance reading with no cells in the well. As seen in Figure 1, there is a clear trend for the
15,000 initial cell density group that when the cells are treated with 5-FU, the cells are less viable, which
leads to less ATP production from the cells and therefore a lower absorbance reading when tested with
the spectrophotometer.
When the initial cell density was dropped to 7,500 cells, a similar trend can be seen in the tumor
response to the drug treatment. The control group had the highest cell viability across all the treatment
groups and was significantly different from all other treatment groups. The 5µg/µL and 10µg/µL
treatment groups were not significantly different from each other but were significantly lower than the
control viability and significantly higher than the 20µg/µL treatment viability. Once again, the 20µg/µL
treatment caused the cell viability to decrease to a range that isn’t significantly different from the
baseline reading. This trend is illustrated in Figure 2 with the control producing an absorbance reading of
around 900, then dropping to an average of around 500 with the 5µg/µL and 10µg/µL treatment groups
and then finally nearing just above 200 with the 20µg/µL treatment. When comparing the 7,500 initial cell
density to the 15,000 cell density the main difference is that the 5µg/µL treatment doesn’t produce a
significantly different absorbance reading than the 10µg/µL treatment. This could be due to the ratio of 5FU to cell being higher in the wells with only 7,500 cells initially.
When comparing the cell viability within the same 5-FU concentration groups and varying cell
densities, the trends are similar but not every change in cell density causes a significantly different
viability reading. For example, looking at the 5µg/µL 5-FU concentration, the 15,000 initial cell density
wells had the highest viability significantly when compared to any other treatment condition. For the
7,500 cells, the viability was significantly lower, and then once again when moving to the 3,750 the
viability is significantly lower. The 5µg/µL comparison is the only drug concentration where a decrease in
cell density caused the viability to be in a different grouping in the Tukey comparison. Looking at the
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10µg/µL treatment groups, the 15,000 and 7,500 cell wells were grouped together meaning their viability
readings weren’t significantly different from one another. However, the 3,750 cell wells had a significantly
lower viability. Lastly, the 20µg/µL treatment, because of how potent it was, caused all three cell densities
to be in the same grouping as the least viable treatment conditions. Looking at the comparison between
interactions, the highest cell viability was from the highest cell density and lowest drug concentration,
which is what was expected. These values came from the Tukey comparisons for the interaction in
Appendix O.
The experimental results achieved from the cell viability assay closely resemble the expected
results from previous literature. After looking at the study by Zhao, et al, the researchers used a CCK-8
assay to determine that the number of viable SW620 cells decreased after being treated with 5-FU [11].
The same decrease in viable cells after a 5-FU treatment was observed using the ATPase cell viability
assay. By getting similar results as previous researchers, it meant that the ATPase assay was a conclusive
way to determine SW620 viability and that the research could progress into culturing the cells on a 2D
ECM hydrogel. Furthermore, a different research experiment set out to compare the efficacy of three
different viability assays, one of which being an ATP luminescent assay on the SW620 cell line treated with
5-FU [35]. The purpose of the study was to compare viability assays against each other, however, the
trend in viability they saw when treating the SW620 cells with 5-FU was the same trend in the SW620
viability study conducted for this thesis. As the drug concentration of 5-FU increased, the cell viability, also
measured by an ATP assay, decreased.
A limitation of the experimental design was that a multi-pipettor wasn’t used to seed the cells in
each of the wells in the well plate and to distribute the drug treatment. Instead, a micropipettor was used
to manually fill each one of the 96 wells individually. This could result in slight variation, on the scale of
nanoliters, in media volume, cell solution volume, and 5-FU volume within each well. The potential
variation in volume between each well was mitigated by using enough replicates (n=8) to ensure the
power of the experiment was greater than 85%. Because there were multiple replicates of each
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experimental condition, the variation between wells would average out to the intended experimental
conditions.
Macro Validation
Both the macros created for the 2D ECM analysis and the 3D ECM analysis needed to be
manually validated to ensure that the tumors were being analyzed properly. The validation process for
both macros was the same and it involved manually tracing the tumors in ImageJ and comparing the
recorded area from the manual selection to the recorded area from the macros. The difference in area
was then divided by the manually recorded area to determine the percent error of the macro. For the 2D
ECM macro, the percent error was 6.4 ± 6.0%. The total, calculated by summing the areas of all tumors
analyzed in the validation process, was 721.8um2 for the macro and was 712.8um2 for the manually
recorded tumors. The standard error for the total area was 186.7µm2. For the 3D ECM macro, the percent
error was 6.6 ± 4.9%. The total area for the macro was 1598.3µm2 and was 1604.9µm2 for the manually
traced tumors. The total areas had an average standard error of 271.9µm2. The low percent errors for
both macros mean that the analysis method used for the tumors was accurate.
Limitations in the macro validation process were that there was only one manual reviewer which
could lead to bias when analyzing the tumors. Additionally, only a small sample size of tumors was
analyzed due to the time component of manually analyzing the tumors and comparing them to the
macro. Only one image for the 2D and 3D experiments were analyzed to validate the macro and the
control for the highest cell density was the experimental condition used in both validation processes
because it guaranteed enough tumors to test.
2D ECM Hydrogel Experiment
After the expected linear response was achieved in the 96-well plate, the cell densities were
scaled up to match the increased volume of the chamber slides. For the 2D hydrogel experiment, the
same trend from the first experiment was seen where cell viability decreased as the drug concentration
increased. Instead of measuring viability with absorbance readings, this experiment measured cell viability
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using average tumor size, total tumor area, and total tumor count metrics. Looking at Figure 16, a similar
trend for all three cell densities can be seen. The control group has the highest total tumor area and as
the drug concentration increases, the total tumor area decreases. The trend is the most linear with the
highest cell density at 30,000 cells. The trend for the 15,000 cell initial density is similar but the drop in
area between the 5µg/µL and 10µg/µL drug concentrations isn’t significant. Finally, the 7,500 cell initial
density has a similar trend as well but both 5µg/µL and 10µg/µL drug concentrations had a total tumor
area of zero.
The next metric analyzed in this experiment was the total tumor count per well in the chamber
slides. Looking at Figure 17, there are two distinct trends seen. The first trend is with the two lowest initial
cell densities with the 7,500 and 15,000 cell wells. With both these experiments, the control group had
the highest average tumor count and the 5µg/µL and 10µg/µL drug concentrations were both around the
same count but significantly lower than the control groups for their respective densities. The 7,500 cells
had no tumors analyzed for the 5µg/µL and 10µg/µL drug concentrations because the drug concentration
was too potent for the low density of cells and no tumors survived the 48 hour treatment period. With
the 30,000 initial cell density, the trend is different because the 5µg/µL drug treatment caused an
increase in the average tumor count per well compared to the control group. The 10µg/µL drug treatment
then dropped the tumor count back lower than the tumor count in the control group. Considering that
the total tumor area for the 30,000 initial cell density followed a linearly decreasing trend, it can be
interpreted that the tumors in the 5µg/µL treatment were smaller than the tumors in the control. An
explanation for the increase in tumor count once the 5µg/µL of 5-FU is added is that the large tumors
initially formed in the 48 hour culture period without drug interaction are broken into multiple, smaller
tumors after the drug is introduced. Because the tumors were large enough, the smaller tumors formed
were still able to survive the 5µg/µL concentration. However, when the tumors broke apart once
introduced to the 10µg/µL treatment, the drug concentration was too potent and the tumor count and
size decreased because more cell apoptosis occurred.
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The last metric analyzed was the average tumor size for each experimental condition. Looking at
Figure 18, the same trend can be seen across all three cell densities. The trend withing the same cell
density groups is that the control has the significantly highest average tumor size and then the average
size for the 5µg/µL and 10µg/µL treatment groups are similar but significantly lower than the control
group. Once again, the data for the two drug treatments on the 7,500 cells is zero because the drug was
too potent for the low initial cell density and no tumors survived the 48-hour treatment period. Within
the 15,000 initial cell density groups, the 10µg/µL treatment has an average size that is slightly lower than
the 5µg/µL average size but because of the standard deviation within each group, the two means aren’t
considered statistically different form each other. The same can be said about the 10µg/µL treatment
group having a slightly higher average tumor size than the 5µg/µL treatment group in the 30,000 cell
density wells.
According to the research by Slater, Cindy et al, after the SW620 cells were treated with 5-FU,
the researchers observed a reduction in tumor size [4]. In the 2D ECM experiment conducted, tumor size,
tumor count, and total tumor area were all calculated to determine the tumor response to the 5-FU
treatment. Another group of researchers created a 2D SW620 culture model to validate a 3D model they
were trying to construct. These researchers created the 2D model by seeding the SW620 cells on top of
Matrigel, a hydrogel used for ECM construction, in a 96 well plate and then used a viability assay on the
culture to determine the effect of 5-FU [36]. Although their research used Matrigel instead of a fibrin gel,
the SW620 cells were still evaluated in a 2D culture model after being treated with 5-FU. Their work with
the 2D SW620 model concluded that the cell viability decreased as the concentration of 5-FU increased.
This result is expected as it is the same response the SW620s had without being cultured on a hydrogel.
Because this thesis used confocal microscopy to characterize the tumor response in the 2D model, the
tumor size, total tumor area, and tumor count were all used as analogs to cell viability. Therefore, if the
cells were expected to have a lower cell viability, the decrease could be expected to be seen by a decrease
in these three metrics. All three metrics were used to determine that the tumors were responding as
expected from the literature. Once the statistical analysis confirmed that the tumor size was decreasing
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across all cell densities as a result of the 5-FU treatment, the next step was to create a 3D culture and
replicate the same expected results.
A limitation of the 2D hydrogels was that the surface of the gels wouldn’t form uniformly across
all the wells, meaning that the surface geometries that the cells were adhered to was slightly different
between each well. The problem that arises from the uneven surface is that within an individual well, not
all the cells would be on the same plane. The effect this would have on the results was mitigated by using
a confocal microscope to be able to image deeper into the sample so that each image would clearly show
the tumors. This was less of an issue in the 3D hydrogels because the cells were cultured inside the gels
instead of on the surface.
3D ECM Hydrogel Experiment
A 3D tumor culture is the next significant improvement in quantifying the tumor response to the
5-FU treatment because 3D cultures can better mimic the native tumor microenvironment. It is also
important to study the effect of the drug in a 3D environment because the drug is initially placed on top of
the hydrogel and needs to perfuse through the sample to reach the majority of the cancer cells. Whereas
in 2D, all the cancer cells were in a single monolayer on top of the gel, so the drug had immediate contact
with the cells when it was first administered. The cell densities had to be slightly increased for the 3D
experiment because there was a greater working volume within the gel that the cells could grow in.
Because the drug concentrations were calculated based on the culture volume the cells had access to, if
the cell densities weren’t increased, the drug would be too potent. It is important to find an ideal range of
cell densities for the 3D tumor culture because the gel culture will eventually be injected into microfluidic
devices using cell densities that are validated to respond to the drug treatment.
Looking at the main effects plot in Figure 19, the average tumor size is constantly decreasing as
the drug concentration increases. And looking at the main effects plot in Appendix Y for tumor count, the
tumor count first increases from the control and then decreases after the 2.5µg/µL 5-FU treatment. From
these trends, the conclusion can be made that under control conditions, there are approximately 27 large
tumors per well. When the tumor culture is treated with 2.5µg/µL of 5-FU, the large tumors start to break
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apart from the cell-drug interactions and the culture in the well begins to form smaller, yet more
numerous tumors. This is indicated by the increase in tumor count, yet the decrease in average tumor
size. Additionally, the total tumor area, shown in Appendix AB, increases during the 2.5µg/µL 5-FU
treatment. This would suggest that while that drug concentration is potent enough to weaken the cell-cell
interactions within the initial tumors in the culture, the cells can still thrive in a culture with that low of a
concentration. As the treatment concentration increases to 5µg/µL, the initial tumors still break apart but
by the end of the 48-hour treatment period, the majority of the tumors in the culture have been
exterminated from the drug. The decrease in average tumor size, tumor count, and total tumor area
observed at this drug concentration supports that theory. Finally, the 10µg/µL 5-FU treatment is enough
to almost exterminate the entire tumor culture, once again indicated by the decrease in average tumor
size, tumor count, and total tumor area.
The most telling results from the 3D experiment was the box plot for average tumor size shown
in Figure 23. Across all three cell densities tested, there is a clear trend in average tumor size where the
size decreases as the drug concentration increases with the tumor size bottoming out between the
5µg/µL and 10µg/µL 5-FU treatments. Because the tumors responded as expected based on the literature,
the combination of cell density and drug concentration could be used to seed the hydrogel in the
microfluidic device and treat the culture. Additionally, it is clear that the drug treatment was the main
factor in reducing the tumor size because the box plot shows that across the cell densities within the
same drug concentration group, the average tumor size remained around the same size with no statistical
differences between cell densities.
Looking at the Tukey comparison in Appendix V for the interaction of cell density and drug
concentration on average tumor size, it is clear that the drug concentration is what was affecting the
tumor size, not the cell density. The three highest mean tumor sizes are the control groups for all three
cell densities. The control, or 0µg/µL 5-FU treatment, for each density was in its own grouping that was
significantly higher than all other experimental conditions. The next distinct grouping was the 2.5µg/µL 5FU treatment for all three cell densities, which had significantly lower average tumor sizes than the
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control groups but significantly higher average tumor sizes than the remaining experimental groups. The
last distinct grouping consists of the 5µg/µL and 10µg/µL 5-FU treatments for all three cell densities and
this grouping had significantly lower average tumors sizes than all other treatment conditions.
Looking at the Tukey comparison in Appendix Y for the interaction between cell density and drug
concentration on total tumor count, the main observation is with the 10µg/µL -5FU treatment group. All
three cell densities that were treated with 5µg/µL of 5-FU were in the lowest grouping for tumor count
compared to the other treatment conditions. Although there wasn’t a distinct trend between increases
drug concentration and cell density and getting a linear increase or decrease in tumor count, the 10µg/µL
concentration had been observed to be too potent, hence why all cell densities treated with it had low
tumor counts. The significantly highest tumor counts were with the 120,000 cell density and 90,000 cell
density with the 2.5µg/µL treatment which were the only two treatment conditions in Grouping A.
The last Tukey comparison for this experiment was for the interaction between cell density and
drug concentration on total tumor area which can be found in Appendix AB. For this comparison, half of
the treatment conditions were placed in Grouping D, the lowest grouping for total tumor area. The six
treatment conditions in this grouping were all three cell densities with the 5µg/µL and 10µg/µL 5-FU
treatments. Only the three cell densities treated with 10µg/µL 5-FU were significantly lower than the
other treatment conditions outside Grouping D. It was once again expected that the highest drug
concentration, regardless of cell density, would produce the lowest total tumor area. There were only
four treatment conditions that had significantly higher total tumor areas than all conditions in Grouping D.
Those conditions were the 120,000 and 60,000 cell densities treated with 2.5µg/µL 5-FU and the control
for the 120,000 and 90,000 cell densities. Given the theory that the low dosage of the drug broke up the
tumors into smaller tumors but wasn’t potent enough to cause apoptosis in all cells, it would be expected
that the highest cell density treated with 2.5µg/µL 5-FU would have the highest total tumor area, which is
what was observed in this experiment.
Similar to the 2D ECM experiment, the efficacy of this experiment was validated using the
expected results from the literature published by Slater, Cindy et al [4]. As well as the literature, this
66

experiment was also compared to the 2D ECM experiment to determine if the tumors were responding
similarly in the 3D culture as they were in the 2D culture. Another study used a combination of cell medias
and Matrigel to create a 3D SW620 culture model where they tested 5-FU and other antitumor agents.
They were looking at how increasing the molarity of the 5-FU treatment would affect the metabolic
activity of the SW620 tumor culture. They found that increasing the 5-FU would cause a decrease in
metabolic activity [37]. This study is similar to the 3D fibrin ECM experiment conducted for this thesis
because both experiments involved treating SW620 tumors in a 3D hydrogel culture model treated with
5-FU. Instead of directly studying metabolic activity, this thesis looked at the change in tumor size, total
tumor area, and total tumor count in the 3D model. These three metrics can be used as an analog to
metabolic activity, because if the metabolic activity decreases within the tumor culture, the cells won’t be
proliferating as quickly, leading to decreases in the three metrics. Once the cell densities and drug
concentrations were validated for the 3D culture, meaning the tumors in the 3D culture were responding
to the 5-FU as expected, the hydrogels were ready to be injected into the microfluidic device for the final
testing of this experiment.
One of the potential limitations in the 3D ECM hydrogel model was that the drug had to perfuse
through the gel to reach the cells instead of being with the cells immediately after the treatment. With
the cell viability assay and the 2D ECM gel model, the drug was instantly able to react with the cells after
being delivered with the media after the initial 48-hour culture period. With the 3D gels, however, the
drug would have reached the cells at different times in the culture depending on how deep the cells were
located in the gel. The effects of the uneven drug exposure on each tumor were mitigated by the 48-hour
treatment period before the cells were fixed to be imaged. Based on how the tumors behaved as
expected when treated, the 48-hour time period was sufficient for the 5-FU to permeate the entire gel.
Additionally, with the confocal microscope, the focal plane was able to be moved through the depth of
the gel to find the plane each tumor was on. For the majority of the z-stacks, 20 individual slices were
taken covering approximately 25-30um in depth for each gel. The total depth of the gel was
approximately 50-60um. It was found that most of the tumors were found in the upper half of the gel
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because there were more media perfusion near the top of the gels. The confocal microscope had the
capabilities to image the full depth of the gel but in most cases, it wasn’t necessary as there weren’t many
tumors further than 30um deep in the gel.
3D Fibrin Hydrogel Cultured in Microfluidic Device
Looking at the average tumor size shown in Figure 20, the same trend is seen as in the previous
experiment. The 5-FU treatment decreases the tumor size when compared to the control. The 2.5µg/µL
and 5µg/µL treatments were closer in average size in the microfluidic devices than they were in the 3D
hydrogels in the chamber slides. This can be due to the fact that the drug is being perfused throughout
the hydrogel inside the device instead of sitting on top the of the hydrogel in the chamber slides. The
added perfusion in this experiment looks to make the 5-FU treatment more potent. This can also be seen
with the total tumor area shown in Figure 25. There is a large difference in total area when comparing the
control device to the two experimental devices. In the three microfluidic devices that the statistics were
taken from, the tumors responded as expected to the treatment, validating the proof of concept of
injecting a 3D fibrin gel with a cell culture into a microfluidic device as a method for accurate drug testing.
A group of researchers published a study, from Parlato et al, where they were able to
successfully create a 3D microfluidic platform to evaluate SW620 interaction with dendritic cells when
exposed to anti-cancer agents [14]. The study found that the SW620s responded in the microfluidic device
similarly to how they would have responded in vivo. This suggests that the SW620s in the injected 3D
fibrin hydrogel would also respond as expected in vivo. Although this experiment only acted as a proof of
concept, the tumors still showed a decrease in average size, tumor count, and total tumor area after
being exposed to the 5-FU meaning the experiment was a success.
Looking at the control device, the tumor cells were able to evenly distribute throughout the first
half of the device, starting at the ECM inlet location and reaching near the media perfusion inlet and
outlets. Additionally, there were two main tumor formations that were around 170,000 and 70,000µm2
compared to the majority of the tumors that were only 1,000-2,000µm2. This heavily skewed the standard
deviation for the tumors in the control device but it shows that the SW620 cancer cells can be successfully
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cultured and have a high proliferation rate inside the microfluidic device. Compared to the tumor
distribution seen with the 5µg/µL and 10µg/µL 5-FU treatment devices, the tumors weren’t able to
distribute across the device and stayed near the ECM inlet. This result can be expected after looking at the
cell distribution in the 3D ECM gel experiment. Because the source of media was the ECM inlet, the cells
were less likely to stray from the nutrient source when treated with 5-FU.
One of the limitations of working in the microfluidic devices is that the media was perfused
through the device over the course of the treatment period. This proves to be a challenge when getting all
the 5-FU through the device without over treating the tumors. The procedure to ensure the majority of
the 5-FU was perfused through the device was to manually pipette the drug solution through the device
until all the old media was pushed out of the outlet. Once the device was entirely filled with the drug
solution and complete media, a pipette with the same drug solution and media was put in the inlet to
continue to perfuse throughout the 48-hour treatment period.
Future Work
The immediate next step to take this research forward would be to continue running the last
experiment but utilizing more devices so that a proper two-factor analysis of variance experience could be
established. This would require testing three densities and three drug concentrations (one being the
control), with a separate device for each experimental condition. The objective of this experiment would
be once again to find the range of cell densities and drug concentrations that produce a linear response so
that the regression equation could be used to approximate appropriate dosages within that range. The
statistical results from this experiment would be similar to the results achieved from the second and third
experiments. The current experiment in the microfluidic devices acted as a proof of concept of being able
to inject a 3D tumor culture into a device and be able to perfuse media and the drug treatment through
the device. Being able to incorporate more devices would be able to take this experiment past a proof of
concept and be a more accurate, statistically backed experiment.
Another way to further validate the results of these experiments would be to run an additional
control for cells treated only with DMSO. Because the 5-FU compound is dissolved in DMSO to administer
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the treatment, a DMSO only control would provide useful insight on how the cells respond to the DMSO,
and can show the separate effect that the 5-FU will have on the tumor cultures. This would involve
changing the current methods in two ways. The first would be that three individual 5-FU solution would
need to be made instead of the current method, which uses one master mix that the 5-FU concentrations
are then pulled from. By creating three separate solutions, varying amounts of 5-FU can be dissolved into
an equal amount of DMSO. For the DMSO control group, the cells would then be treated with the same
volume of DMSO that is being used to dissolve the 5-FU. A previous study conducted by the Liaoning
Cancer Hospital and Institute in China compared their SW620 control groups to their DMSO control
groups and found that the DMSO didn’t significantly lower the cell proliferation rates of the cultures [34].
Another future step that can be taken with this experiment is adding vascularization to the fibrin
hydrogels so that the tumor cultures would be grown with human umbilical vein endothelial cells
(HUVECs) and hepatocyte growth factor (HGF). A lack of a vascular network in hydrogels puts a limitation
on the nutrition that the cells are able to get, especially at the core of the hydrogels [16]. As tissue
constructs have become more complex to mimic in vivo environments, 3D vascular networks have
become a necessity. One method for seeding HUVECs into the hydrogel is by attaching the HUVECs on a
needle and transferring it onto the inner surface of the hydrogel by electrochemical desorption, a process
that can modify surface proteins [17]. Another method for seeding HUVECs into the microfluidic device is
by centrifuging the HUVECs into a pellet and then resuspending the pellet in a thrombin solution at high
cell density. The thrombin and HUVECs were then combined with a fibrinogen solution and then injected
into the microchannels of the device [19]. This second method where the HUVECs were mixed with the
thrombin would be able to be completed with the resources in the current lab space. Following the
methods outlined for creating the 3D ECM hydrogel for this experiment, the SW620s in fibrinogen and
EGM could be combined with the HUVECs in the thrombin to create an injectable gel with both cancer
tumors and vascularization.
As well as adding changes to the experimental method and adding more complexity to the
hydrogels, another option for taking the research forward is by treating the tumor cultures with different
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drugs. Another potential candidate for treating the tumors in this model is irinotecan hydrochloride.
Irinotecan is a camptothecin derivative that has antitumor properties against SW620 cells. Once absorbed
by the body, irinotecan is metabolically activated into 7-ethyl-10-hydroxycamptothecin (SN-38). In the
United States, irinotecan was approved in combination with 5-FU for treatment of metastatic colorectal
cancer [18]. A study used a gene expression microarray assay to be able to identify which genes were
altered by a SN-38 treatment. The study found that SN-38 targeted genes involved in DNA replication,
transcription, apoptosis, and cell cycle regulation. The RT-PCR analysis confirmed changes in expression of
14 genes after the SN-38 treatment [20]. If by treating the tumor cultures in the microfluidic devices with
irinotecan, or its metabolized SN-38, and cell apoptosis is observed, it further validates the microfluidic
device as a testing platform for anti-cancer agents.
By conducting the four experiments in this study using different culture platforms to eventually
create an injectable 3D ECM hydrogel to culture tumors in a microfluidic device, it allowed the final
microfluidic model to be easily validated. Because the 5-FU treatments showed a decrease in tumor size,
total tumor area, and tumor count in the three microfluidic devices, the microfluidic device model is
validated as a way to screen antitumor agents in an in vitro environment that mimics the in vivo
environment these agents would otherwise be tested in. This model can be used to continue to be
validated with other antitumor agents, like irinotecan, and the formula for the injectable ECM gel can be
adjusted depending on the cell line and drug.
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APPENDICES
Appendix A
Complete RPMI Recipe:
1.
2.
3.
4.
5.
6.
7.
8.

Gather RPMI base media, FBS (Fetal Bovine Serum), P/S (Penicillin/ Streptomycin), and
Fungizone
Heat all reagents in a 37⁰C water bath
Add 250mL of RPMI base media into a media filter
Add 28mL of FBS (10% volume of total complete RPMI media)
Add 2.8mL of P/S (1% volume of total complete RPMI media)
Add 280uL of Fungizone (.1% of total complete RPMI media)
Attach the aspirator to the media filter
Store complete RPMI media in the refrigerator between uses
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Appendix B
Plating:
1.
2.
3.
4.

A cryovial containing 1mL of frozen SW620 cells was put into a 37⁰C water bath to thaw
The cells were then pipetted into a T-75 flask with 11mL of complete RPMI media
The flask was then put in an incubator at 37⁰C and 5% C02 to mimic in vivo conditions
After 48 hours, the media was aspirated and replaced with 12mL of fresh complete RPMI
media
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Appendix C
Expansion:
1.
2.

Remove a confluent T-75 flask from the incubator and aspirate the media
Add 5mL of DPBS (Dulbecco’s Phosphate Buffer Solution) so that it covers the growth surface
of the flask
3. Aspirate the DPBS
4. Add 3mL of Trypsin and let it sit in the flask for 2 minutes
5. Move the flask to an inverted microscope and use the 4X objective lens to observe the cells
6. Once the cells are no longer adhered to the surface of the flask, bring the flask back into the
BSC and add 3mL of complete RPMI media to neutralize the Trypsin
7. For a 1:2 pass, the cell solution was split evenly into 2 new T-75 flasks (3mL of cell solution
into each flask)
8. 9mL of complete RPMI was then added to each flask to reach the working volume of 12mL
9. The flasks were then put back into the incubator at 37⁰C and 5% C02
10. The media was then changed every 48 hours
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Appendix D
Freezing:
1.
2.
3.

Follow the first 6 steps of the Expansion protocol
Transfer the cell solution to a 50mL conical
Add the same volume of water to a new 50mL conical to act as a counterbalance in the
centrifuge
4. Centrifuge the cell solution for 2minutes 30 seconds at 3rcf (relative centrifugal force)
5. While the cells are in the centrifuge, make the freezing media by combining 80% of complete
RPMI, 10% FBS, and 10% DMSO (Dimethyl Sulfoxide) by volume
a. 1mL of freezing media is needed for each cryovial to be used and an extra 1mL of
freezing media should be added to account for media lost in the syringe filter
6. Transfer the freezing media to a syringe filter and filter it into a new 15mL conical
7. Remove the cell solution from the centrifuge
8. Aspirate the media out of the conical taking precaution to not disturb the pellet of cells at
the bottom
9. Resuspend the pellet in freezing media
10. Transfer 1mL of the cells in the freezing media to the cryovials
11. Store the cryovials in a -80⁰C freezer for 24 hours
12. Transfer the cryovials to a Dewar to be stored in liquid nitrogen
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Appendix E
Cell Counting:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

11.
12.
13.
14.

15.

Follow the first 6 steps of the Expansion protocol
Transfer the cell solution to a 50mL conical
Add the same volume of water to a new 50mL conical to act as a counterbalance in the
centrifuge
Centrifuge the cells for 2 minutes and 30 seconds at 3rcf
Aspirate the media taking precaution to not disturb the pellet
Resuspend the pellet in 10mL of complete RMPI
Transfer 100uL of cell solution into a 1.5mL Eppendorf tube
Add 400uL of Trypan Blue to the Eppendorf tube
Transfer 50uL of the cell/Trypan solution into a hemocytometer
Put hemocytometer in an inverted microscope and use 4X objective
to find the counting grid then use the 10X objective to zoom in to
count the cells (Figure 1)
Count the number of alive cells in the 4 labelled quadrants in Figure
1 and average the number of cells
Take the average number and multiply by 104 cells/ml to account for
the volume in the hemocytometer
Multiply by the inverse of the ratio of cell solution to cell/Trypan
Figure 1: Hemocytometer counting
solution (in this case the ratio is 5)
grid. The 4 quadrants used to count
This will result in a value of cells/mL which can be multiplied by
the cells are labeled 1-4.
the volume used to resuspend the pellet in Step 6 to get a total
cell count
An example of the above calculations:
a. Quadrant 1: 44 cells, Quadrant 2: 42 cells, Quadrant 3: 61 cells, Quadrant 4: 55 cells
b. Average cells/quadrant: 50.5 cells
c. 50.5*104*5 = 2.5E6 cells/mL
d. 2.5E6 cells/mL * 10mL = 25 million cells
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Appendix F
Serial ATP Dilution:
1.
2.
3.
4.
5.
6.
7.

10uL of 10mM ATP was diluted into 9.9mL of complete RPMI to get a 10uM ATP solution
1mL of that solution was then diluted into 9mL of complete RPMI to get a 1uM ATP solution
100uL of the 1uM ATP solution was pipetted into the assigned wells before the plate was
analyzed
1mL of the 1uM ATP solution was diluted into 9mL of complete RMPI to get a 100nM ATP
solution
100uL of the 100nM ATP solution was pipetted into the assigned wells before the plate was
analyzed
1mL of the 100nM ATP solution was diluted into 9mL of complete RPMI to get a 10nM ATP
solution
100uL of the 10nM ATP solution was pipetted into the assigned wells before the plate was
analyzed
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Appendix G
CellTiter-Glo Reagent Recipe:
1.
2.
3.
4.

Thaw the CellTiter-Glo Buffer, and equilibrate to room temperature
Equilibrate the lyophilized CellTiter-Glo Substrate to room temperature
Transfer the CellTiter-Glo Buffer into the bottle containing the CellTiter-Glo Substrate to
reconstitute the lyophilized enzyme/substrate mixture to form the CellTiter-Glo reagent
Mix by gently vortexing, swirling, or inverting the contents to obtain a homogeneous
solution
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Appendix H
2-Dimensional Fibrin Gel:
1.
2.
3.
4.
5.
6.
7.
8.

1mL Eppendorf tubes were autoclaved using the “Pouch Setting 1” autoclave feature
The total volume of gel needed was calculated taking into account that each well would have
80uL of gel
To create the fibrinogen solution, 10mg/mL of fibrinogen was put in a 15mL conical with the
calculated volume of Human Endothelial Growth Media (EGM).
The conical was placed on a rocker for 10 minutes to mix the reagents
80uL of the fibrinogen solution was aliquoted into each Eppendorf tube
Thrombin was pulled out of the refrigerator and kept on an ice pack in the BSC. The chamber
slides were also cooled for 5 minutes on an ice pack in the BSC
The chamber slides were then moved to the area under the icepacks in the BSC
4uL of thrombin was added to one of the 80uL aliquots and the resulting solution (Fibrin)
was quickly pipetted into one of the wells. After all the wells were filled with the Fibrin gels,
the chamber slides were placed in the incubator at 37⁰C and 5% C02 for 30 minutes so the
gels could cure.
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Appendix I
Fixing Protocol:
1.
2.
3.
4.
5.
6.

Bring the chamber slides into the fume hood
Aspirate the media
Add an equal amount of 4% PFA (paraformaldehyde) as the media aspirated to each well
Let sit for 10 minutes then aspirate the PFA
Add an equal amount of DPBS as the media aspirated to each well
Put the chamber slides in an empty micropipette box and cover the box with aluminum foil
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Appendix J
3-Dimensional Fibrin Gel:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

13.

1mL Eppendorf tubes were autoclaved using the “Pouch Setting 1” autoclave feature
The total volume of gel needed was calculated taking into account that each well would have
80uL of gel
To create the fibrinogen solution, 10mg/mL of fibrinogen was put in a 15mL conical with the
calculated volume of Human Endothelial Growth Media (EGM).
The conical was placed on a rocker for 10 minutes to mix the reagents
While the solution is being mixed, count the cells using the cell counting procedure
previously mentioned
Once the total cell count is calculated, split the cell solution into three 15mL conicals so that
each conical has enough cells for its respective cell density
Centrifuge each conical for 2 minutes and 30 seconds at 3CRF to pellet the cells
Aspirate the media from the conicals and add the fibrinogen solution to the conicals
80uL of the fibrinogen and cell solution was aliquoted into each Eppendorf tube
Thrombin was pulled out of the refrigerator and kept on an ice pack in the BSC. The chamber
slides were also cooled for 5 minutes on an ice pack in the BSC
The chamber slides were then moved to the area under the icepacks in the BSC
4uL of thrombin was added to one of the 80uL aliquots and the resulting solution (Fibrin)
was quickly pipetted into one of the wells. After all the wells were filled with the Fibrin gels,
the chamber slides were placed in the incubator at 37⁰C and 5% C02 for 30 minutes so the
gels could cure.
Once cured, 300uL of complete RPMI was added in each well
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Appendix K
Macro to Analyze 2D Gel Experiment:
run("Set Scale...", "distance=512 known=636.396 pixel=1 unit=um");

Image scale is now in um

run("Gaussian Blur...", "sigma=2"); Gaussian Blur is applied to image
run("Color Threshold..."); The color threshold is used to change the color image to b&w
// Color Thresholder 2.0.0-rc-69/1.52i
// Autogenerated macro, single images only!
min=newArray(3);
max=newArray(3);
filter=newArray(3);
a=getTitle();
run("HSB Stack");
run("Convert Stack to Images");
selectWindow("Hue");
rename("0");
selectWindow("Saturation");
rename("1");
selectWindow("Brightness");
rename("2");
min[0]=0;
max[0]=255;
filter[0]="pass";
min[1]=0;
max[1]=255;
filter[1]="pass";
min[2]=16;
max[2]=255;
filter[2]="pass";
for (i=0;i<3;i++){
selectWindow(""+i);
setThreshold(min[i], max[i]);
run("Convert to Mask");
if (filter[i]=="stop") run("Invert");
}
imageCalculator("AND create", "0","1");
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imageCalculator("AND create", "Result of 0","2");
for (i=0;i<3;i++){
selectWindow(""+i);
close();
}
selectWindow("Result of 0");
close();
selectWindow("Result of Result of 0");
rename(a);
// Colour Thresholding------------run("Set Measurements...", "area fit area_fraction display redirect=None decimal=3");

Define metrics

run("Analyze Particles...", "size=1000-20000 show=Outlines display summarize");

Records area

Results:
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Appendix L
Macro to Analyze 3D Gel Experiment:
run("Set Scale...", "distance=512 known=636.396 pixel=1 unit=um");
run("Z Project...", "projection=[Sum Slices]");

Image scale is now in um

All image slices are stacked together and summed

run("Gaussian Blur...", "sigma=2"); Gaussian Blur filter applied to summed images
run("8-bit");

Image type changes from RGB color to 8-bit grayscale

setAutoThreshold("Huang dark"); Color threshold changes image from grayscale to b&w
//run("Threshold...");
//setThreshold(24, 255);
setOption("BlackBackground", true);
run("Convert to Mask");
run("Set Measurements...", "area fit area_fraction display redirect=None decimal=3");

Define metrics

run("Analyze Particles...", "size=1000-20000 show=Outlines display summarize");

Calculate area

Results:
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Appendix M
Descriptive Statistics:
Results for Cell Density = 3.75
Statistics
Drug
Variable Concentration Mean StDev Minimum Maximum
Viability 5

330.7 44.7

276.5

409.1

10

324.68 20.94

298.48

361.00

20

238.74 11.32

226.12

254.87

Results for Cell Density = 7.50
Statistics
Drug
Variable Concentration Mean StDev Minimum Maximum
Viability 5

524.7 57.2

446.6

590.6

10

469.6 28.5

434.7

521.5

20

235.76 10.38

223.61

249.76

Results for Cell Density = 15.00
Statistics
Drug
Variable Concentration Mean StDev Minimum Maximum
Viability 5

692.2 169.3

470.3

966.0

10

490.6 168.4

317.9

848.8

20

238.37 14.21

219.34

255.65
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Appendix N
P-Value Calculations:
Analysis of Variance
Source

DF

FSeq SS Contribution Adj SS Adj MS Value

Cell Density

2

379608

18.31% 379608 189804 26.70

Drug Concentration

2

971546

46.85% 971546 485773 68.33

4

274614

13.24% 274614 68654

Error

63

447887

21.60% 447887

Total

71

2073654

Cell Density*Drug
Concentration

Source

7109

100.00%

P-Value

Cell Density

0.0000000040012538

Drug Concentration 0.0000000000000002
Cell Density*Drug
Concentration

0.0000037274806502

Error
Total

Model Summary
S

RRR-sq sq(adj) PRESS sq(pred)

AICc

BIC

84.3167 78.40% 75.66% 584995 71.79% 856.90 876.06

Coefficients
Term
Constant

SE
Coef Coef 95% CI

TPValue Value VIF

393.93

9.94 (374.07,
413.78)

39.64 0.000

3.75

-95.9

14.1 (-124.0, 67.8)

-6.82 0.000 1.33

7.50

16.1

Cell Density

14.1

(-12.0,
44.2)

1.14 0.257 1.33

88

9.66

Drug Concentration
5

121.9

14.1

(93.9,
150.0)

8.68 0.000 1.33

10

34.4

14.1 (6.3, 62.4)

2.45 0.017 1.33

3.75 5

-89.3

19.9 (-129.0, 49.5)

-4.49 0.000 1.78

3.75 10

-7.7

19.9

(-47.4,
32.0)

-0.39 0.698 1.78

7.50 5

-7.3

19.9

(-47.0,
32.4)

-0.37 0.715 1.78

7.50 10

25.3

19.9

(-14.5,
65.0)

1.27 0.209 1.78

Cell Density*Drug
Concentration
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Appendix O
Tukey Pairwise Comparison:
Grouping Information Using the Tukey Method and 95% Confidence
Cell
Density N

Mean Grouping

15.00

24 473.715 A

7.50

24 410.016

3.75

24 298.052

B
C

Means that do not share a letter are significantly different.
Tukey Simultaneous Tests for Differences of Means
Difference
of
Cell
Density Difference
SE of Simultaneous
T- Adjusted
Levels
of Means Difference
95% CI
Value P-Value
7.50 - 3.75

112.0

24.3 (53.6, 170.3)

4.60

0.000

15.00 3.75

175.7

24.3 (117.3, 234.0)

7.22

0.000

15.00 7.50

63.7

24.3 (5.4, 122.0)

2.62

0.029

Individual confidence level = 98.05%
Grouping Information Using the Tukey Method and 95% Confidence
Drug
Concentration N

Mean Grouping

5

24 515.867 A

10

24 428.291

20

24 237.624

B
C

Means that do not share a letter are significantly different.
Tukey Simultaneous Tests for Differences of Means
Difference of
Drug
Concentration Difference
SE of Simultaneous
T- Adjusted
Levels
of Means Difference
95% CI
Value P-Value

90

10 - 5

-87.6

24.3

(-145.9, 29.2)

-3.60

0.002

20 - 5

-278.2

24.3

(-336.6, 219.9)

-11.43

0.000

20 - 10

-190.7

24.3

(-249.0, 132.3)

-7.83

0.000

Individual confidence level = 98.05%
Grouping Information Using the Tukey Method and 95% Confidence
Cell
Density*Drug
Concentration N

Mean Grouping

15.00 5

8 692.215 A

7.50 5

8 524.656

B

15.00 10

8 490.559

B

7.50 10

8 469.632

B

3.75 5

8 330.731

C

3.75 10

8 324.681

C

3.75 20

8 238.742

C

15.00 20

8 238.370

C

7.50 20

8 235.759

C

Means that do not share a letter are significantly different.
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Factorial Plots:
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Appendix P
Power Calculations:
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Appendix Q
Descriptive Stats for 2D Hydrogel Experiment:
Results for Cell Dens. = 7.5
Statistics
Drug
Variable Conc.

SE
N N* Mean Mean StDev Minimum Maximum

Total
Area

Control

6 0 19111

5557 13613

7941

45635

Total
Count

Control

6 0 5.67

1.41 3.44

3.00

12.00

Average Control
Size

6 0 3480

626 1533

2157

6381

Results for Cell Dens. = 15.0
Statistics
Drug
Variable Conc.

SE
N N* Mean Mean StDev Minimum Maximum

Total
Area

10

2 0 5177

1967 2781

3210

7144

5

3 0 5954

2183 3781

2951

10200

Control

6 0 43710

8095 19829

26898

75208

10

2 0

1.00 1.41

2.00

4.00

5

3 0 3.000 0.577 1.000

2.000

4.000

Control

6 0 10.50

2.29 5.61

5.00

18.00

2 0 1695.6

90.4 127.8

1605.2

1786.0

5

3 0 1865

343

595

1475

2550

Control

6 0 4428

413 1012

3254

5874

Total
Count

Average 10
Size

3.00

Results for Cell Dens. = 30.0
Statistics
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Drug
Variable Conc.
Total
Area

Total
Count

SE
N N* Mean Mean StDev Minimum Maximum

10

10 0 16232

3351 10597

2880

37443

5

7 0 25664

4503 11914

10676

41763

Control

3 0 39856 15085 26128

23953

70011

10

10 0 6.10

1.41 4.46

2.00

17.00

5

7 0 9.71

1.34 3.55

5.00

14.00

Control

3 0 8.33

3.33 5.77

5.00

15.00

10 0 2730

282

893

1440

4135

5

7 0 2555

131

347

2135

3010

Control

3 0 4860

135

234

4667

5121

Average 10
Size
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Appendix R
Tukey Comparison for 2D Hydrogel Experiment:
Comparisons for Average Tumor Size:
Tukey Pairwise Comparisons: Cell Dens.
Grouping Information Using the Tukey Method and 95% Confidence
Cell
Dens. N

Mean Grouping

30.0 20 3423.37 A
15.0 11 2723.57 A

B

7.5

B

6 1865.34

Means that do not share a letter are significantly different.
Tukey Simultaneous Tests for Differences of Means
Difference
of Cell
Dens.
Difference
SE of Simultaneous
T- Adjusted
Levels
of Means Difference
95% CI
Value P-Value
15.0 - 7.5

858

491 (-349, 2065)

1.75

0.203

30.0 - 7.5

1558

536 (239, 2877)

2.91

0.018

30.0 - 15.0

700

375 (-223, 1622)

1.87

0.165

Individual confidence level = 98.06%
Tukey Pairwise Comparisons: Drug Conc.
Grouping Information Using the Tukey Method and 95% Confidence
Drug
Conc.

N

Mean Grouping

Control 15 4285.49 A
10

12 1921.48

B

5

10 1805.32

B

Means that do not share a letter are significantly different.
Tukey Simultaneous Tests for Differences of Means
Difference
of Drug
Conc.
Difference
SE of Simultaneous
T- Adjusted
Levels
of Means Difference
95% CI
Value P-Value

96

5 - 10

-116

389 (-1072, 840)

-0.30

0.952

Control 10

2364

439 (1284, 3444)

5.39

0.000

Control - 5

2480

436 (1408, 3553)

5.69

0.000

Individual confidence level = 98.06%
Comparisons for Total Tumor Area:
Tukey Pairwise Comparisons: Cell Dens.
Grouping Information Using the Tukey Method and 95% Confidence
Cell
Dens. N

Mean Grouping

30.0 20 28935.4 A
15.0 11 19899.8 A
7.5

6 -403.2

B

Means that do not share a letter are significantly different.

Tukey Pairwise Comparisons: Drug Conc.
Grouping Information Using the Tukey Method and 95% Confidence
Drug
Conc.

N

Mean Grouping

Control 15 35657.8 A
5

10 9670.2

B

10

12 3103.9

B

Means that do not share a letter are significantly different.
Comparisons for Tumor Count
Tukey Pairwise Comparisons: Cell Dens.
Grouping Information Using the Tukey Method and 95% Confidence
Cell
Dens. N

Mean Grouping

30.0 20 8.66533 A
15.0 11 6.07573 A
7.5

6 2.82782 A
97

Means that do not share a letter are significantly different.
Tukey Pairwise Comparisons: Drug Conc.
Grouping Information Using the Tukey Method and 95% Confidence
Drug
Conc.

N

Mean Grouping

Control 15 8.69514 A
5

10 5.66784 A

B

10

12 3.20590

B

Means that do not share a letter are significantly different.

Factorial Plots:
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Appendix S
General Linear Models for 2D Hydrogel Experiment:
GLM for Tumor Area:
Analysis of Variance
Source

DF

Cell Density
Drug
Concentration
Error

Adj SS

FAdj MS Value

2 153807038 76903519

P-Value

5.83 0.0033218276333626

2 300974472 150487236 11.41 0.0000175796631204
267 3521397270 13188754

Lack-of-Fit
Pure Error
Total

2

5975343

2987671

0.23 0.7984955840264274

265 3515421928 13265743
271 3825829405

GLM for Total Area:
Analysis of Variance
Source

DF

Adj SS

FAdj MS Value

P-Value

Cell
Dens.

2 2427706321 1213853161

Drug
Conc.

2 4734379525 2367189763 11.25 0.0001998462592170

Error
Lackof-Fit

5.77 0.0072606993721601

32 6734843164 210463849
2

578375249 289187624

Pure
Error

30 6156467915 205215597

Total

36 11681163343

1.41 0.2600530833444157

GLM for Tumor Count:
Analysis of Variance
Source

DF Adj SS

Adj
FPMS Value Value
100

Cell
Dens.

2 99.52 49.76

2.55 0.093

Drug
Conc.

2 127.21 63.60

3.27 0.051

Error

32 623.23 19.48

Lackof-Fit

2 81.41 40.70

Pure
Error

30 541.83 18.06

Total

36 769.68

2.25 0.123
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Appendix T
3D ECM Descriptive Stats:
Results for Density = 60
Statistics
Variable Conc.
Area

SE
N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

134 0 1460

113 1309

113 494

1218 1981

9006

2.5

380 0 1131.7

75.5 1472.3

100.4 534.2

893.0 1265.3

16962.0

5.0

253 0 631.4

23.4 371.9

106.6 404.8

582.4 784.8

2320.5

104 1292

100 165

10.0 155 0

652

341

640

12899

Results for Density = 90
Statistics
Variable Conc.
Area

SE
N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

163 0 1522.8

91.0 1161.9

111.2 614.9 1356.5 1989.9

5651.4

2.5

178 0 1081.5

66.3 884.1

103.5 441.9

852.0 1384.3

4852.7

5.0

220 0 532.8

24.3 360.0

100.4 272.3

457.3 680.9

2340.6

10.0

91 0 394.6

23.0 219.4

100.4 237.9

367.7 511.4

1174.2
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Results for Density = 120
Statistics
Variable Conc.
Area

SE
N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

186 0 1568

103 1403

100 557

1322 1953

8394

2.5

321 0 1037.2

45.3 811.2

102.0 553.1

838.9 1246.8

6728.3

5.0

254 0 448.5

17.6 281.3

100.4 250.3

407.9 587.5

2138.2

10.0 150 0 427.1

39.9 488.1

100.4 193.1

333.7 555.8

5436.7
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Appendix U
3D ECM GLM:
Factor Information
Factor Type Levels Values
Density Fixed

3 60, 90, 120

Conc.

4 0.0, 2.5,
5.0, 10.0

Fixed

Analysis of Variance
Source

FAdj MS Value

DF

Adj SS

Density

2

4458323

Conc.

3 364230038 121410013 127.16 0.0000000000000000

Density*Conc.

6

2229162

6592041

1098673

Error

2473 2361230250

954804

Total

2484 2746732481

2.33 0.0970548950250072

1.15 0.3301913816425197

Model Summary
S

RRR-sq sq(adj) sq(pred)

977.141 14.03% 13.65% 13.24%

Coefficients
Term
Constant

SE
TPCoef Coef Value Value VIF
907.3

21.1 43.08 0.000

Density
60

61.5

29.2

90

-24.3

31.4 -0.78 0.438 1.59

0.0

609.4

38.1 16.00 0.000 1.33

2.5

176.2

32.3

P-Value

2.11 0.035 1.63

Conc.

5.45 0.000 1.29
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5.0

369.7

33.2 -11.13 0.000 1.25

60 0.0

118.4

55.2 -2.15 0.032 1.99

60 2.5

-13.3

43.3 -0.31 0.758 1.97

60 5.0

32.3

46.3

0.70 0.485 1.82

90 0.0

30.4

54.5

0.56 0.577 1.83

90 2.5

22.4

49.8

0.45 0.653 1.92

90 5.0

19.6

48.7

0.40 0.687 1.77

Density*Conc.
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Appendix V
3D Tumor Size Tukey Comparisons:
Grouping Information Using the Tukey Method and 95% Confidence
Density

N

Mean Grouping

60

922 968.797 A

90

652 882.922 A

120

911 870.079 A

Means that do not share a letter are significantly different.
Tukey Pairwise Comparisons: Conc.
Grouping Information Using the Tukey Method and 95% Confidence
Conc.

N

Mean Grouping

0.0

483 1516.68 A

2.5

879 1083.46

5.0

727 537.59

C

10.0 396 491.33

C

B

Means that do not share a letter are significantly different.
Tukey Pairwise Comparisons: Density*Conc.
Grouping Information Using the Tukey Method and 95% Confidence
Density*Conc.

N

Mean Grouping

120 0.0

186 1567.50 A

90 0.0

163 1522.75 A

60 0.0

134 1459.78 A

60 2.5

380 1131.68

B

90 2.5

178 1081.53

B

120 2.5

321 1037.18

B

60 10.0

155 652.32

C

60 5.0

253 631.40

C

90 5.0

220 532.83

C

120 5.0

254 448.52

C

120 10.0

150 427.11

C

90 10.0

91 394.57

C
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Means that do not share a letter are significantly different.

107

Appendix W
3D ECM Tumor Count Descriptive Statistics:
Results for T_Density = 60
Statistics
SE
Variable T_Conc. N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

T_Count 0.0

6 0 22.33

2.38 5.82

12.00 18.00

23.50 27.25

28.00

2.5

9 0 42.22

4.21 12.63

26.00 30.50

39.00 55.00

60.00

5.0

9 0 28.11

2.66 7.99

16.00 20.50

28.00 35.50

38.00

10.0

9 0 17.22

3.79 11.38

3.00 9.50

17.00 24.00

40.00

Results for T_Density = 90
Statistics
SE
Variable T_Conc. N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

T_Count 0.0

6 0 27.17

2.70 6.62

19.00 21.25

27.50 31.25

38.00

2.5

6 0 29.67

2.65 6.50

21.00 26.25

28.50 33.50

41.00

5.0

9 0 24.44

3.11 9.33

6.00 19.00

26.00 32.00

37.00

10.0

9 0 10.11

2.52 7.56

0.00 1.50

11.00 16.00

21.00
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Results for T_Density = 120
Statistics
SE
Variable T_Conc. N N* Mean Mean StDev Minimum

Q1 Median

Q3 Maximum

T_Count 0.0

6 0 31.00

2.70 6.60

26.00 26.75

27.00 39.25

40.00

2.5

6 0 53.50

2.55 6.25

46.00 46.75

55.00 59.00

59.00

5.0

9 0 28.22

4.11 12.34

7.00 17.00

31.00 39.00

42.00

10.0

9 0 16.67

5.13 15.39

0.00 3.00

19.00 27.00

45.00
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Appendix X
3D ECM Tumor Count GLM:
Factor Information
Factor

Type

Levels Values

T_Density Fixed

3 60, 90, 120

T_Conc.

4 0.0, 2.5, 5.0, 10.0

Fixed

Analysis of Variance
Source

DF Adj SS Adj MS F-Value

P-Value

T_Density

2

1300

650.0

6.50 0.0024099726412330

T_Conc.

3

8525

2841.7

28.42 0.0000000000011815

T_Density*T_Conc.

6

1175

195.8

1.96 0.0814000417182178

Error

81

8100

100.0

Total

92

19133

Model Summary
S

R-sq R-sq(adj) R-sq(pred)

9.99979 57.67%

51.92%

45.50%

Coefficients
Term

Coef SE Coef T-Value P-Value VIF

Constant

27.56

1.06

26.05

0.000

60

-0.08

1.47

-0.06

0.955 1.36

90

-4.71

1.51

-3.12

0.002 1.37

0.0

-0.72

1.97

-0.37

0.715 1.72

2.5

14.24

1.89

7.52

0.000 1.71

5.0

-0.63

1.72

-0.37

0.716 1.60

60 0.0

-4.42

2.78

-1.59

0.116 2.31

60 2.5

0.51

2.55

0.20

0.842 2.13

60 5.0

1.27

2.42

0.52

0.602 2.11

90 0.0

5.04

2.80

1.80

0.075 2.35

90 2.5

-7.42

2.74

-2.71

0.008 2.26

90 5.0

2.23

2.45

0.91

0.365 2.15

T_Density

T_Conc.

T_Density*T_Conc.
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Appendix Y
3D ECM Tumor Count Tukey Comparison:
Tukey Pairwise Comparisons: T_Density
Grouping Information Using the Tukey Method and 95% Confidence
T_Density

N

Mean Grouping

120

30 32.3472 A

60

33 27.4722 A

B

90

30 22.8472

B

Means that do not share a letter are significantly different.

Tukey Pairwise Comparisons: T_Conc.
Grouping Information Using the Tukey Method and 95% Confidence
T_Conc.

N

Mean Grouping

2.5

21 41.7963 A

5.0

27 26.9259

B

0.0

18 26.8333

B

10.0

27 14.6667

C

Means that do not share a letter are significantly different.

Grouping Information Using the Tukey Method and 95% Confidence
T_Density*T_Conc.

N

Mean Grouping

120 2.5

6 53.5000 A

60 2.5

9 42.2222 A

B

120 0.0

6 31.0000

B

C

90 2.5

6 29.6667

B

C

120 5.0

9 28.2222

B

C

60 5.0

9 28.1111

B

C

90 0.0

6 27.1667

B

C

D

90 5.0

9 24.4444

C

D

60 0.0

6 22.3333

C

D

60 10.0

9 17.2222

C

D

120 10.0

9 16.6667

C

D

90 10.0

9 10.1111

D

Means that do not share a letter are significantly different.
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Factorial Plots:
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Appendix Z
3D ECM Total Tumor Area Descriptive Statistics:
Results for T_Density = 60
Statistics
Variable T_Conc.
T_Area

N N* Mean SE Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

6

0 32602

4615

11305

13948 23180

34032 43407

44198

2.5

9

0 47782

6875

20624

26068 28075

46138 66717

81808

5.0

9

0 17749

2045

6136

9200 12059

17779 23595

24589

10.0

9

0 11234

3650

10951

10745 16539

35699

434

3021

Results for T_Density = 90
Statistics
Variable T_Conc.
T_Area

N N* Mean SE Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

6

0 41368

7096

17380

22873 29804

36077 54645

72311

2.5

6

0 32085

4463

10933

11173 27250

34313 38387

43382

5.0

9

0 13025

1993

5979

3243

8680

12480 16358

24183

10.0

9

0

1018

3054

0

372

3990

113

4500

6920

7618

Results for T_Density = 120
Statistics
Variable T_Conc.
T_Area

N N* Mean SE Mean StDev Minimum

Q1 Median

Q3 Maximum

0.0

6

0 48593

5792

14187

33519 38794

43524 61548

72560

2.5

6

0 55489

5126

12555

41181 48185

53217 61771

78661

5.0

9

0 12658

2342

7026

2643

5133

15417 19269

20427

10.0

9

0

2223

6668

0

635

6767 10839

20656

7118
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Appendix AA
3D ECM Total Tumor Area GLM:
Factor Information
Factor

Type

Levels Values

T_Density Fixed

3 60, 90, 120

T_Conc.

4 0.0, 2.5, 5.0, 10.0

Fixed

Analysis of Variance
Source

DF

Adj SS

Adj MS F-Value

P-Value

T_Density

2 1009698666 504849333

3.96 0.0227816279643070

T_Conc.

3 23982821426 7994273809

62.77 0.0000000000000000

T_Density*T_Conc.

6 2095635589 349272598

2.74 0.0177630938895455

Error

81 10316054947 127358703

Total

92 37831585856

Model Summary
S

R-sq R-sq(adj) R-sq(pred)

11285.3 72.73%

69.03%

63.40%

Coefficients
Term
Constant

Coef SE Coef T-Value P-Value VIF
26975

1194

22.60

0.000

60

367

1659

0.22

0.825 1.36

90

-4358

1703

-2.56

0.012 1.37

0.0

13880

2228

6.23

0.000 1.72

2.5

18144

2138

8.49

0.000 1.71

5.0

-12497

1945

-6.42

0.000 1.60

60 0.0

-8620

3135

-2.75

0.007 2.31

60 2.5

2296

2873

0.80

0.427 2.13

60 5.0

2905

2733

1.06

0.291 2.11

90 0.0

4872

3158

1.54

0.127 2.35

90 2.5

-8676

3095

-2.80

0.006 2.26

90 5.0

2905

2760

1.05

0.296 2.15

T_Density

T_Conc.

T_Density*T_Conc.
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Appendix AB
3D ECM Total Tumor Area Tukey Comparison:
Tukey Pairwise Comparisons: T_Density
Grouping Information Using the Tukey Method and 95% Confidence
T_Density

N

Mean Grouping

120

30 30964.7 A

60

33 27341.9 A

B

90

30 22617.0

B

Means that do not share a letter are significantly different.

Tukey Pairwise Comparisons: T_Conc.
Grouping Information Using the Tukey Method and 95% Confidence
T_Conc.

N

Mean Grouping

2.5

21 45118.9 A

0.0

18 40854.2 A

5.0

27 14477.5

B

10.0

27

B

7447.5

Means that do not share a letter are significantly different.

Tukey Pairwise Comparisons: T_Density*T_Conc.
Grouping Information Using the Tukey Method and 95% Confidence
T_Density*T_Conc.

N

Mean Grouping

120 2.5

6 55489.3 A

120 0.0

6 48592.6 A

B

60 2.5

9 47782.1 A

B

90 0.0

6 41368.1 A

B

60 0.0

6 32601.8

B

C

90 2.5

6 32085.3

B

C

60 5.0

9 17749.4

C

D

90 5.0

9 13024.8

C

D

120 5.0

9 12658.3

C

D

60 10.0

9 11234.4

D

120 10.0

9

7118.5

D

90 10.0

9

3989.6

D

Means that do not share a letter are significantly different.
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Factorial Plots:
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Appendix AC
2D ECM Total Tumor Area Summary:
Cell Density (cells/well)

Drug Concentration (µg/µL)

Total Tumor Area(µm2)

0

39856 ± 15,085

5

25,664 ± 4,503

10

16,232 ± 3,351

0

43,710 ± 19,829

5

5,954 ± 3,781

10

5,177 ± 2,781

0

19,111 ± 13,613

5

0

10

0

Drug Concentration (µg/µL)

Average Tumor Count

0

8.33 ± 5.77

5

9.71 ± 3.55

10

6.10 ± 4.46

0

10.50 ± 5.61

5

3.00 ± 1.00

10

3.00 ± 1.41

0

5.67 ± 3.44

5

0

10

0

30,000

15,000

7,500

2D ECM Total Tumor Count Summary:
Cell Density (cells/well)

30,000

15,000

7,500
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2D ECM Average Tumor Size Summary:
Cell Density (cells/well)

30,000

15,000

7,500

Drug Concentration (µg/µL)

Average Tumor Size (µm2)

0

4860 ± 234

5

2555 ± 347

10

2730 ± 893

0

4428 ± 1012

5

1865 ± 595

10

1696 ± 128

0

3480 ± 1533

5

0

10

0
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Appendix AD
3D ECM Total Tumor Area Summary:
Cell Density (cells/well)

Drug Concentration (µg/µL)

Total Tumor Area (µm2)

0

48,593 ± 14,187

2.5

55,489 ± 12,555

5

12,658 ± 7,026

10

7,118 ± 6,668

0

41,368 ± 17,380

2.5

32,085 ± 10,933

5

13,025 ± 5,979

10

3,990 ± 3054

0

32,602 ± 11,305

2.5

47,782 ± 20,624

5

17,749 ± 6,136

10

11,234 ± 10,951

120,000

90,000

60,000

3D ECM Total Tumor Count Summary:
Cell Density (cells/well)

Drug Concentration (µg/µL)

Tumor Count

0

31.00 ± 6.60

2.5

53.50 ± 6.25

5

28.22 ± 12.34

10

16.67 ± 15.39

0

27.17 ± 6.62

2.5

29.67 ± 6.50

5

24.44 ± 9.33

10

10.11 ± 7.56

0

22.33 ± 5.82

2.5

42.22 ± 12.63

5

28.11 ± 7.99

10

17.22 ± 11.38

120,000

90,000

60,000

120

3D ECM Average Tumor Size Summary:
Cell Density (cells/well)

120,000

90,000

60,000

Drug Concentration (µg/µL)

Average Tumor Size (um2)

0

1,568 ± 1,403

2.5

1,037.2 ± 811.2

5

448.5 ± 281.3

10

427.1 ± 488.1

0

1,522.8 ± 1,1161.9

2.5

1,081.5 ± 884.1

5

532.8 ± 360.0

10

394.6 ± 219.4

0

1,460.0± 1,309.0

2.5

1,131.7 ± 1,472.3

5

631.4 ± 371.9

10

652 ± 1,292
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